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1 Introduction and aim of the work 
1.1 Introduction 
Radiopharmaceuticals, or medicinal radio-compounds, are a group of pharmaceutical 
drugs that have a radioactive labeling atom [1].  As one of the most important basic 
tools in radiopharmaceutical research, radiopharmaceuticals enable target-specific 
delivery of radionuclides to the diseased tissues, the interactions of which with tissues 
can be revealed through biodistribution characteristics. Nuclear medicine procedures 
use radiopharmaceuticals. In hospitals, radiopharmaceuticals must be guided by 
physicians only for nuclear medicine applications. Radiopharmaceuticals can be 
classified by their chemical and physical properties or by the specific binding capability 
or other biological interactions [2].  
 
Radiopharmaceuticals are administered via intravenous injection. The correlation of the 
radiopharmaceutical properties of radiopharmaceuticals with their in vivo behavior is 
always the main point during study. Knowing information such as the redox properties, 
in vitro stability, stereochemistry, charge, and lipophilicity (solubility) of the 
radiopharmaceuticals in some cases can help predict the in vivo behavior. Generally 
speaking, negatively charged compounds tend to clear through the kidneys; many 
positively charged ions accumulate in the heart; and an overall neutral complex is 
required for crossing the blood-brain barrier. Lipophilic complexes are usually cleared 
through the hepatobiliary system and may accumulate in fatty tissues. Stereochemistry 
is important as well for targeting specific receptors. Although thermodynamic stability of 
the complex is often an important factor, kinetic stability may better predict in vivo 
stability [3]. Ideally, suitable radiopharmaceutical agents should have the following 
characteristics: good ratio of specific to non-specific binding, high selectivity for 
biochemical target/process of interest, suitable pharmacokinetics, excellent in vivo 
stability (metabolism should not negatively affect functional binding), good safety profile 
(lack of toxicity to subject), potential for clinical translation, time and cost-effective 
synthesis, signal amplification, and multiplexing capabilities.  
 
Radiopharmaceuticals used in nuclear medicine today could fall into two main 
categories by medical applications, useful in imaging and/or in therapy. For imaging 
applications, they provide a method for non-invasively visualizing human formation and 
physiology to support for the diagnostic of human diseases and to monitor therapy. For 
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therapeutic application, they deliver a toxic payload selectively, for instance to a tumor 
site, which damages the diseased tissue through the emission of energetic particles. 
The particle emission can be β particles, α particles, or Auger electrons (e−) [4]. 
 
Radiopharmaceuticals can be classified by radionuclide categories. In these categories, 
radiohalogens have played a key role. Among all radiohalogens, 18F is probably the 
single most important radionuclide used in PET [5], which is owing to the successful 
application of glucose-mimetic 2-deoxy-2-[18F]fluoro-D-glucose ([18F]-FDG). The 
subsequent discovery of abnormal accumulates in tumors makes it as a major clinical 
tool in cancer diagnosis through PET imaging. [18F]FDG is now the standard 
radiotracer and the most commonly used substance for PET imaging and cancer 
patient management [6]. 
 
Other than radioactive halogens, the majority of radiopharmaceuticals currently 
available for applications in nuclear medicine are based on radiometals. One of the 
most prevalently used radionuclide is 99mTc. The production and medical use of 99mTc 
rapidly expanded across the world since 1960s. The reason is benefiting from the 
availability via portable 99Mo/99mTc generators with a minimal cost, continuous 
improvements of the gamma cameras and the development of tremendous Technetium 
chemistry that has allowed for its incorporation into a plethora of formulations for a 
variety of drugs.  
 
Designation of radiometals based radiopharmaceuticals was always accounted for one 
of the largest amount among all the publications related [7]. In general, it consists of 
four main following parts: the selection of radionuclide; suitable chelators (ligands) for 
coupling or chelating; targeting biomolecules with great specificity and targeting 
potential; and sometimes pharmacokinetic modifying linker. As the part for specific 
binding, most of the targeting biomolecules are small organic or inorganic compounds 
with definite composition. While, they can also be macromolecules such as monoclonal 
antibodies and antibody fragments. These small molecules, peptides, aptamers, 
monoclonal antibodies, etc. were utilized as carriers to transport radionuclide 
selectively to diseased tissues specifically.  
 
As the mandatory needs for radiolabeling of biomolecules with a metallic radionuclide, 
chelators are the most popular concerns in the development of radiopharmaceuticals. 
These chelating agents have been termed “bifunctional chelating agents” since they 
have a metal binding moiety function and then also possess a chemically reactive 
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functional group [8]. The labeling would be difficult if the metal ion forms insoluble 
hydroxides at physiological pH.  Thus, it is necessary that the coupling or chelating 
agent complexes and stabilizes the radiometal ion, which is one of the functions of 
chelator. Due to different radiometals have significant difference in their coordination 
chemistry, and the complex was largely determined by the nature and oxidation state, 
and require coupling or chelating agents with different donor atoms and chelator 
frameworks. The most suitable chelator should tightly bind a radionuclide ion so that 
when injected into a patient, the targeting molecule can deliver the ion without any 
radionuclide loss from the radiopharmaceutical. Moreover, it needs a high 
thermodynamic stability and kinetic inertness, under physiological conditions, are 
required to prevent the release and dissociation of the radiometal ion from its complex 
and thus avoid the accumulation in non-targeted organs. Conjugation group (chelator’s 
reactive moiety) is the other function of chelator in radiopharmaceuticals. Different 
Biomolecules should be conjugated easily after the chelator bind a radiometal tightly. A 
stable link between the radionuclide and the carrier molecule is the primary prerequisite 
for in vivo applications.  
A number of conjugation techniques have been developed for the coupling of 
biomolecules.  The conjugation groups for attachment of a chelator to the biomolecule, 
such as isothiocyanate, N-hydroxysuccinimide ester (NHS), maleimide (MAL), 
anhydride, and bromo- or iodoacetamide. 
 
Absorption, distribution and metabolic changes of radiopharmaceuticals in the body 
after administration have directly relation with effects of medical applications. 
Therefore, the pharmacokinetics should be optimized by a careful design about the 
attachment of radiometal ion chelate so as to reduce the accumulation in non-targeted 
organs, while maintaining the uptake rate at the site of interest that lead to an 
improvement of the target to background/blood (T/B). There are several ways to modify 
pharmacokinetics of radiopharmaceuticals, which include chemical modification of the 
biomolecule (e.g. various hydrophilic groups, such as poly aspartic acid) or chelates 
(e.g. different charge and hydrophilicity), the use of linker, and the choice of co-ligands 
for radiometal chelation.  Specifically, a pharmacokinetic modifying linker was needed 
especially when pre-chelate is very “large”, which keep radiometal chelate away from 
the receptor binding motif to minimize possible interference with receptor binding by the 
radiometal ion chelate. The linker region can be varied in order to modify 
pharmacokinetic properties of the substance, especially excretion kinetics. Including 
these several types cationic, anionic, neutral or metabolically cleavable [9].  
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As the foundation of all facts above, radionuclide and targeting unit are the two most 
important parts, as the following the role of radionuclides will be elucidated in more 
detail. As the radiation source, selection of radionuclide is largely dependent on 
medical application of the radiopharmaceutical. Several factors must be considered in 
choosing a particular radionuclide for therapeutic applications, such as physical half-
life, the chemical properties of radionuclide, energy of the particle emission, type of 
particle emission, specific activity, and the cost and availability of the radionuclide. 
In order to maximize the dose to the target and minimize dose to normal tissue, the 
half-life of radionuclide must match the pharmacokinetics of the radioactive drug. For 
example, radioimmunotherapy (RIT) is a combination of internal radiation therapy and 
immunotherapy. When injected into the patient’s bloodstream, they bind to cancer cells 
and deliver a high dose of radiation directly to the tumor. It normally takes at least 4 
days for antibodies to reach maximum uptake at the target site [10]. So, when choosing 
a suitable therapeutic radionuclide for monoclonal antibodies, it is important to consider 
this factor. If labeling with a too short half-life radionuclide will result in most of the dose 
being administered in normal tissues or blood, with little to none reaching the target 
site. On the other hand, we can choose short-lived radionuclide for faster clearing small 
molecules or peptides labeling to achieve maximum dose delivery in the target tissue.  
 
The radiation doses are highly dependent on type of particle emission (α particles, β 
particles, and Auger electrons) and the energy (especially for β particles or electrons). 
α particles emit high linear energy transfer (LET) radiation and produce very high 
localized ionization densities in cells, which are therefore most effective in cell killing; 
however, their range is short and best suited for small tumors; α particles deposited in 
tumors deliver minimal irradiation of nearby tissues.  Auger emitters produce very low 
energy electrons that have very short ranges and are considered a form of high LET 
radiation. Because of their subcellular ranges, the Auger-emitting radionuclides must 
be deposited within or extremely close to the nucleus of the cell for maximum 
effectiveness. β particles are low LET radiation and generally have ranges in soft tissue 
of a few micrometers to a few centimeters. Thus, low to medium energy β particle 
emitting radionuclides (e.g., 177Lu) are considered more effective for treating small 
tumors, while high energy β particle-emitting radionuclides (e.g., 90Y) are more 
appropriate for treatment of larger tumors [4]. Therefore, the specific cancer to be 
treated, tumor size and location, and the non-target radiation dose delivered by the 
radiopharmaceutical were the most critical issues in cancer treatment. Besides, the 
radiation dose delivered to non-target tissues and organs will be a critical factor in 
determining the maximum activity (MBq) that can be administered to the patient.  
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Therefore, the choice of type and energy of the particle emission is largely determined 
by the size of the lesion or tumor being treated, site of delivery, whether the tumor is 
homogeneous, and whether the dose can be delivered uniformly to each cell. Then, 
specific activity is a measure of the radioactivity per unit mass of the compound; 
Increasing the specific activity of a radionuclide leads to the improvement percentage 
of radioactive atoms and the deliverable dose in case of receptor binding substances. 
Besides, the cost and availability of the radionuclide ultimately determines whether it is 
used for clinical. For example, generators usually provide the radionuclide at a 
relatively low cost. Thus, there are so many factors in radionuclide selection. Luckily, 
availability of a wide range of radionuclides makes it possible.  The in vivo use of 
radionuclides prompted the development of the field of nuclear medicine. Besides the 
commonly used medical radionuclides like 99mTc,18F, 64Cu, Neves et al. selected 20 new 
studied potential alternative radionuclide candidates shows promising physical 
characteristics for medical uses, including 73Ga, 75Se, 87mSr, 97Ru, 103Ru, 113Sn, 113mIn, 
117Sb, 123Sn, 131Cs, 139Ce, 141Ce, 149Eu, 167Tm, 170Tm, 173Tm, 195Au, 195mPt, 197Pt and 
197(m)Hg [11].  Among these proposed radionuclides, 197(m)Hg have great potential for 
radiopharmaceutical applications.   
 
197mHg (T1/2 = 23.8 h, Eγ 134 keV, 34%) and 197Hg (T1/2 = 64.14 h, Eγ 77 keV, 19%, 279 
keV, 6%) are gamma-emitting radioisotope isomers. Because of the emission spectrum 
of photons, 197(m)Hg are suitable for SPECT imaging. Moreover, their Auger and 
conversion electron emission shows us potential of therapeutic with additional interest. 
Since each radionuclide ion has unique aqueous coordination chemistry properties 
[12], mercury also has same properties. The “free” mercury ions must be sequestered 
from aqueous solution using chelators (ligands). Therefore, novel ligands/chelators for 
the radio-mercury labeling have to be developed. Luckily, the unique chemical and 
physical properties as metal which forms water-stable organometallics and strong 
binding properties toward sulfur rich ligands, leads to the chemists’ strong interest on 
mercury already decades ago. But high toxicity, low specific activity and easy volatility 
of 197Hg labeled compounds awakened their interest of medical applications at that 
time. The only remaining application of mercury radioisotopes today are mainly 
environmental studies [13, 14]. Thus, a special topic to precedent new 
radiopharmaceuticals based on mercury radioisotopes is their high specific activity.  
Besides, a large number of articles with broader covering topics ranging from chelators, 
coordination chemistry, environmental sensors could provide us new idea to design the 
chelation for medical application and be a guide for us to find a suitable ligand for 
Introduction and aim of the work 
__________________________________________________________________________________________________________ 
 6 
197(m)Hg radiopharmaceutical applications. 
 
1.2 Aims of the Thesis 
The presented PhD thesis aims at development of radiochemical requirements for 
197(m)Hg labeling substances with promising capability for the theranostic studies. The 
following potentials are needed for radiopharmaceutical applications: suitable 
pharmacokinetics, excellent in vivo stability, high molar activity (low toxicity to subject), 
possibility for clinical translation, effective synthesis specifying which organ or tissue is 
to be targeted. In order to fulfill the aims, the overall objectives of this research 
contained these four following parts briefly: 197(m)Hg production, 197(m)Hg separation and 
197(m)Hg labeling as well as with specific targeted agents, which is like the studies of 
other new potential radionuclides.  
 
 
1.2.1 Major tasks of this work 
 
1. Radionuclide production is always the first step of radiopharmaceutical research. 
The production of n.c.a.197Hg together with the short-lived 197mHg isomer is possible by 
proton or deuteron irradiation of natural gold using a cyclotron, as two promising 
nuclear reactions reported: 197Au(p,n)197(m)Hg reaction  [15, 16], 197Au(d,2n)197(m)Hg 
reaction  [17]. The access to n.c.a. 197(m)Hg should be in sufficient quantity and quality 
so as to be suitable for analytical studies and labeling studies with small scale and for 
animal and other preclinical studies on large scale. Moreover, an improved design by 
studying irradiation time and energy will provide the facility with sufficient quantity and 
quality for imaging and experimental therapeutically purposes. 
 
2. The development of a rapid, reliable method for Hg/Au separation represents an 
important prerequisite for increasing yields which will obtain 197(m)Hg in higher activity 
level with the product elution into a small volume. Here, many of previously established 
methods for mercury separation should be employed, such as distillation of the metal, 
extraction by organic solvents, extraction by resin, etc. However, owing to the different 
mechanisms, these separations do not always give satisfactory results. The purity and 
the final volume of product, efficiency, automatization and total processing time of 
separation procedure, these factors are extremely important for the next coming 
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labeling studies. Therefore, comparison studies need to be employed to select the 
most suitable method enable for labeling studies. 
 
3.  Establishing strategies for development of  197(m)Hg labeled in vivo stable labeling 
units. Several ready-to-use chelators are urgent needed before 197(m)Hg labeling unit 
conjugated with any specific targeted molecules. Numerous factors need to be 
considered for the development of the agents:  
Firstly, a robust synthetic and labeling strategy should be developed for the chelators or 
precursors of 197(m)Hg. Secondly, it should be strongly stable (especially bio-stability) to 
avoid the accumulation of radioactive substances in non-target organs. Thirdly, water 
solubility should be high enough for animal administration and avoid the toxicity of 
organic solvent. Fourthly, high selectivity (specificity) to avoid the transchelation/side 
reaction(s) with other metal ions.  
There are mainly two different approaches for 197(m)Hg labeling, first kind of ligands are 
based on Hg-S bonds, which form 197(m)Hg-S based compounds. It is well known that 
mercury shows strong ability on chelating of thiols, dithiols, disulfide, sulfur based and 
other sulfur rich interacting ligands, which shows great potentials for 197(m)Hg labeling. 
Thus, thiol based chelators should be investigated in the thesis. 197(m)Hg-
organometallics was the second. Mercury is unique among metals in its capability to 
form covalent Hg-C bonds and has its own organic chemistry because the existence of 
large numbers of organic Hg compounds, which shows great potential to be labeled 
and applied in the field of radiopharmacy. 
 
After synthesizing novel agents, its theranostics capability should be accessed by a 
series of in vitro and in vivo studies. Depending on the type of different agents, the 
radiolabeling strategies should be optimized. Soon afterwards, detailed analytical and 
in vitro characterization with high-performance liquid chromatography (HPLC), radio 
thin-layer chromatography (radio-TLC), among other methods should be performed to 
determine several radiochemical behaviors such as labeling efficiency and stability. 
Besides, for the purpose of in vivo animal studies, removal of organic solvents and 
well-suited methods for purification of the radiolabeled units should be developed if 
necessary. Then, the most promising radiolabeled compounds were selected for further 
pharmacokinetic studies in rats. In vivo SPECT imaging studies should be employed 
for further investigations of radiopharmacological behaviors. 
 
4. Followed by the successful development of stable 197(m)Hg chelating units, the 
promising precursors should be conjugated with specific targeted molecules, such as 
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small molecules, peptides, monoclonal antibodies, etc. Radiochemical and 
radiopharmacological behaviors should be investigated in vitro and in vivo to determine 
target-ability, specificity, off-target accumulation and excretion profiles of 197(m)Hg 
labeled compounds. 
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2 Theoretical background and literature survey 
2.1 Theranostics  
2.1.1 General 
Theranostics combines specific targeted therapy based on specific targeted diagnostic 
tests, which was coined in 2002 by Dr. Funkhouser [18]. In the past, it was very 
common to the use separate materials and methods for these two objectives. 
The main advantage of theranostics is to develop one drug that can serve for two 
purposes rather than two separate drugs. The first purpose is about diagnostic test to 
screen the disease state and directly linked to the second purpose, specific therapies 
to improve efficacy and cost effectiveness [19]. With the one-fits-all personalized 
medicine saying to offering the right treatment, for the right patient, at the right time, 
with the right dose, providing a more targeted, efficient pharmacotherapy which has the 
potential to overcome undesirable differences in biodistribution and selectivity that 
currently exist between distinct imaging and therapeutic agents.  
 
In radiopharmacy, the approach of theranostics has two distinct branches that aim to 
fulfill the purpose of personalized medicine. In the first, using a targeting vector labeled 
initially with a diagnostic radionuclide to assess the disease, which followed by 
personalized treatment using the same targeting vector labeled with a therapeutic 
radionuclide. The second branch involves the design, development, and use of agents 
that have both diagnostic and therapeutic capabilities, which deliver therapeutic drugs 
and diagnostic imaging agents at the same time.  Create a safer, more efficient, and 
efficacious means of simultaneously diagnosing, monitoring, and treating disease [20]. 
Agents being designed utilize radionuclides with both potentials that emitting photons 
for imaging and emitting particles useful for therapy, which unite diagnostic and 
therapeutic applications to form a single agent, allowing for diagnosis, therapy and 
treatment response monitoring. 
 
Theranostics is an exciting area with much progress and growth likely yet to come. The 
magnificent outlook is to gain the ability to image and monitor the diseased tissue, 
delivery kinetics, and drug efficacy with the long-term hope of gaining the ability to tune 
the therapy and dose. With the ‘one size fits all’ approach, the theranostic studies will 
make medicine designation move toward an era of more effective and personalized 
treatment approaches. 
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2.1.2 Modalities for diagnostic: PET and SPECT 
SPECT (single photon emission computed tomography) and PET (positron emission 
tomography) are basic modalities to detect the γ-ray emissions of administered 
radiopharmaceuticals by cameras. The imaging system detects gamma rays emitted by 
a tracer (radionuclide), which introduced into the body bound on a biologically active 
molecule. PET is quantitative technique. It has a great advantage over other modalities 
such as MRI and optical imaging. Images of SPECT and PET are acquired over a 
nominally low background signal and require little signal amplification since the gamma 
rays have energies in the KeV range. The technique requires delivery of a radionuclide 
into the patient, normally through injection into the bloodstream so as to obtain reliable, 
real-time information about their in vivo distribution, if necessary. 
 
PET detects pairs of gamma rays which utilizes the unique decay properties of 
positrons. When a positron ejected from the atomic nucleus and slowed down in the 
surrounding tissue, it annihilates with an electron. This procedure (electron and 
positron annihilate each other) is accompanied by the collinear emission of two 511 
keV gamma photons. These two coincident photons are then detected by scintillation 
detectors arranged in a circular array. In comparison to SPECT, PET is usually more 
sensitive. Most of PET radionuclides are difficult and expensive to synthesis or have 
extremely short half-lives, which limits the usage of PET [20].  
 
SPECT is the most widely used imaging technique in clinical studies. When SPECT 
radionuclide decays, one or more gamma rays (ie, photons), having particular energies, 
are released in random directions. SPECT is very similar to conventional nuclear 
medicine planar imaging using a gamma camera. However, it is able to provide true 3D 
information. This information is typically presented as cross-sectional slices through the 
patient, but can be freely reformatted or manipulated as required. Dedicated SPECT 
cameras available in many hospitals allow the gamma rays detection in an energy 
window between 100 and 360 keV. Due to their appropriate nuclear decay properties, 
conventional availability and reasonable cost, 99mTc (t1/2 = 6.03 h), 123I (t1/2 = 13.3 h) and 
111In (t1/2 = 67.2 h) are the most applied SPECT radionuclides in medicine. SPECT 
labeled small molecules are generally cheaper and faster to synthesis and usually have 
a longer half-life compared with PET-labeled compounds. Additionally, SPECT is 
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advantageous because it enables concurrent imaging of multiple radionuclides which 
make it more widely used than PET. However, SPECT radionuclides often require a 
chelating moiety for labeling, which are not found naturally in molecules of interest.  
 
2.1.3 Radionuclide therapy  
Various therapeutic radionuclides have been discovered or developed since the first 
use of radium in the early 1900s. After that, radionuclide therapy has been widely used 
in various clinical malignant and pain management applications. The selection of 
therapeutic radionuclides is very important for clinical applications.  
 
The most commonly used therapeutic radionuclide is 131I, which labeled with sodium 
iodide ([131I]NaI). The treatment is widely known as radioactive iodine (RAI) therapy, 
which uses to treat thyroid-related diseases. Another application of radionuclide 
therapy is in the treatment of bone metastasis with 89Sr, which is preferentially taken up 
at sites of increased bone mineral turnover (five times greater than for normal bone) 
[21]. Radionuclide therapies are also used for the treatment of a variety of carcinomas 
with 131I [22], 90Y, [23], 188Re, [24]; or polycythemia with 32P [25]. 
 
Radioimmunotherapy (RIT) is a type of cancer cell targeting radionuclide therapy which 
uses monoclonal antibodies (mAbs) labelled with a therapeutic radionuclide directed 
against tumor-associated antigens. The ability for the antibody to specifically bind to a 
tumor associated antigen increases the dose delivered to the tumor cells while 
decreasing the dose to normal tissues. During the subsequent decades, various RIT 
radiopharmaceuticals were developed with advances in genetic engineering and 
chelating techniques. Over the decades, an increasing number of new antibodies have 
been studied in clinical trials and have shown positive evidence of efficacy, such as in 
non-Hodgkin’s lymphoma (NHL). The current US Food and Drug Administration (FDA)-
approved radiopharmaceuticals for RIT include 90Y or 111In labeled ibritumomab 
tiuxetan (Zevalin®, approved in 2002) and 131I labeled tositumomab regimen (Bexxar®, 
approved in 2003), both for the treatment of refractory NHL. 
 
In comparison to conventional chemotherapy and external beam radiotherapy, the non-
invasiveness of the procedure and relatively low toxicity make radionuclide therapy 
very attractive. Radionuclide therapy has the advantage of delivering a highly 
concentrated absorbed dose to the targeted tumor while sparing the surrounding 
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normal tissues. In addition, the selective ability of radionuclide therapy is advantageous 
in the treatment of systemic malignancy, such as in bone metastases, where whole 
body irradiation using external beam radiotherapy is impossible. Since the 
administration of therapeutic radionuclides is minimally invasive and the duration of 
treatment is shorter than chemotherapy, targeted radionuclide therapy has become one 
of the most preferred types of cancer therapy. 
 
2.1.4 Radionuclide production for theranostics 
The origin of radionuclides for research and application is the synthetic production. In 
general, there are two main approaches for the production of radionuclides: nuclear 
reactor or cyclotron. There exists a ‘sideway’ option: via a generator system, but also 
generated “parent” radionuclide by nuclear reactor or cyclotron. 
 
Radionuclide production via a nuclear reactor plant is the bombardment of target 
material with neutrons. The neutrons are used as projectiles for the generation of 
neutron rich nuclides. A wide range of radionuclides are made at reactors, from as light 
as 14C to as heavy as 203Hg, with irradiations lasting minutes to weeks. While, for (n,γ) 
production which is the most common, the element does not change and radioisotopes 
are produced, so it is difficult to get the carrier-free product.  
 
The cyclotron approach for radionuclides production has wider types nuclear reactions 
than via reactor. A variety of possible employed projectiles are such as protons, 
deuterons, 3He or 4He bombarding particles (Figure 2.1). Mostly, medical cyclotrons 
use protons as projectiles for the nuclear reactions. In some rare cases, also alpha 
particles or deuterons are accelerated. In a word, the major advantages of cyclotron 
compared with nuclear reactor plants concerning radionuclide production are: small 
construction dimensions; a lower activation of components; a lower neutron 
background; the generation of desired products with high specific activity typically; an 
advantage maybe the production of fewer radionuclide impurities by selecting a defined 
energy window for the employed nuclear reaction. 
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Figure 2.1: Diagram of cyclotron operation from Lawrence's 1934 patent. The "D" shaped electrodes are 
enclosed in a flat vacuum chamber, which is installed in a narrow gap between the two poles of a large 
magnet [26]. 
 
The ‘sideway’ radionuclide generators are devices that produce a useful short-lived 
medical radionuclide (known as “daughter”) by the radioactive transformation of a long-
lived radionuclide (called a “parent”). By having a supply of parent on hand at a nuclear 
reactor, the daughter is continually generated on site. The generator permits ready 
separation of the daughter radionuclide from the parent. Once separation occurs, the 
generator starts generating more daughter that can be again separated in sufficient 
quantity at a later time. 
 
The development of improved production method is always required to minimize 
contaminants no matter which kind of reaction (approach), not only to improve 
production yields but also to increase radiolabeling yields.  
 
 
2.1.5 Metallic radionuclides for theranostics 
A wide variety of different radiometals (Metallic radionuclides) have been utilized in the 
synthesis of coordination compounds [27]. These metal radionuclide complexes are 
utilized in all diagnostic modalities to image a broad array of diseases currently and 
also very important to therapeutic applications (theranostics). Nowadays, nuclear 
imaging is largely dominated by a radiohalogen, 18F [28]. But the studies of radiometals 
are still popular because of following irreplaceable advantages of metallic 
radionuclides: 
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1. There are a large number of metallic radionuclides (Table 2.1) as alternative options 
for the radiopharmaceutical studies [29-32]. It was always easy to find a suitable 
radionuclide of which physical half-life perfectly fits for the biological half-life of the 
targeting vector. Agents with short in vivo residence times can be labeled with 68Ga (t1/2 
~ 68 min) or 99mTc (t1/2 ~ 6 h). While vectors require longer time to reach their target can 
be labeled with 64Cu (t1/2 ~ 12.7 h), 111In (t1/2 ~ 2.8 days), or 89Zr (t1/2 ~ 3.2 days). 
 
 
Radionuclide t 1/2 (h) Decay Mode E (keV) Production  
60Cu 0.4 β
+ (93%) β+, 3920, 3000, 
2000 Cyclotron, 
60Ni(p,n)60Cu EC (7%) 
61Cu 3.3 β
+ (62%) β+, 1220, 1150, 940, 
560 Cyclotron, 
61Ni(p,n)61Cu EC (38%) 
62Cu 0.16 β
+ (98%) β+, 2910 62Zn/62Cu generator EC (2%) 
64Cu 12.7 
β+ (19%) 
β+, 656 Cyclotron, 64Ni(p,n)64Cu EC (41%) 
β− (40%) 
66Ga 9.5 β
+ (56%) β+, 4150, 935 Cyclotron, 63Cu(α,nγ)66Ga EC (44%) 
67Ga 78.2 EC (100%) γ, 93, 184, 300 Cyclotron, 68Zn(p,2n)67Ga 
68Ga 1.1 β
+ (90%) β+, 1880 Cyclotron,
 69Ga(p,2n)68Ge 
68Ge/68Ga generator EC (10%) 
44Sc 3.9 β
+ (94%) γ, 1157 44Ti/44Sc generator 
Cyclotron,44Ca(p,n)44Sc EC (6%) β+, 1474 
47Sc 80.2 β
− (100%) γ, 159 47Ti(n,p)47Sc  β−, 441, 600 
99mTc 6.0 IT (98.6%) γ, 140 
235U fission→99Mo 
99Mo/99mTc generator β−(1.4%) β−, 142 
111In 67.2 EC (100%) γ, 245, 172 Cyclotron, 111Cd(p,n)111m,gIn 
114mIn 49.5 d EC (100%) γ, 190 Cyclotron, 
114Cd(p,n)114mIn 
or 116Cd(p,3n)114mIn 
177Lu 159.4 β− (100%) γ, 112, 208 176Lu(n,γ)177Lu β−, 177, 385, 498 
86Y 14.7 β
+ (33%) β+, 1221 Cyclotron, 86Sr(p,n)86Y EC (66%) 
90Y 64.1 β− (100%) β−, 2280 
90Zr(n,p)90Y 
235U fission→90Sr→90Y 
89Zr 78.5 β
+ (23%) β+, 897 Cyclotron, 89Y(p,n)89Zr EC (77%) 
212Bi 1.1 α (36%) α, 6050 228Pb/212Pb generator β− (64%) β−, 6089 
213Bi 0.76 α (2.2%) α, 5549 228Th/212Pb generator β− (97.8%) β−, 5869 
225Ac 240 α (100%) α, 5600-5830 (6) 
226Ra(p,2n)225Ac 
n-Capture of 232Th → 233U 
→ 225Ac 
 
Table 2.1: Properties of some popular radiometal isotopes (except 197mHg and 197Hg) 
 
In general, by using different bifunctional chelators and radiometals, a wide variety of 
agents could be developed. It facilitates the simplicity and modularity of 
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radiopharmaceuticals designation. For instance, same antibody can be conjugated to 
the chelators such as DTPA and DOTA for labeling with 64Cu for PET imaging, 111In for 
SPECT imaging, or 177Lu for RIT.  Moreover, different radiometals may be labeled 
without changing the chelator at all with the versatile chelators like DOTA, DTPA, and 
NOTA sometimes.  
 
2. The labeling procedure of radiometals probes are generally rapid and can be 
achieved often under mild conditions. The purification procedures are usually simple 
either, typically involving cation exchange chromatography or reverse-phase C-18 
cartridges.  
The properties of radiometals are likely to offer the greatest advantage in this area in 
comparison with radiohalogens labeling, which often require multistep synthesis, harsh 
reaction conditions, and complicated purifications. 
 
3. Many radiometals (e.g., 86Y and 111In) are found due to endocytosis intracellular 
following the uptake of their vector, resulting in increased retention of the activity inside 
the target tissue and higher tumor to background activity ratios than non-residualizing 
radiohalogens (e.g., 18F and 124I) [33]. 
 
4. Metallic radionuclides show great potential of expanding the availability of agents 
with nearby cyclotron facilities. Many radiometals can be produced via portable 
generator systems (e.g., 68Ga and 99mTc) or possess physical half-lives long enough 
(e.g., 64Cu, 111In) so that they can be shipped to laboratories. 
 
To conclude, comparing with other radionuclides, radiometals provide flexibility, 
modularity, and unique producing facility which predominantly possessing the most 
suitable nuclear properties for theranostic applications.  
 
 
2.2 The capability of 197(m)Hg for theranostics 
197mHg together with 197Hg are promising radioisotopes for theranostics. The capability 
of 197(m)Hg for theranostics are illustrated from physical and chemical properties of the 
element, the mainly mercury radioisotopes, to the major decay processes of 197(m)Hg in 
nuclear properties, which are expected to see increased application with the growing 
utilization of both diagnostic and therapeutic radiopharmaceuticals. 
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2.2.1 Properties of the element Hg  
Mercury is a heavy, silvery d-block element (group 12, period 6). It is the only metallic 
element that is liquid at standard conditions for temperature and pressure. Mercury has 
a freezing point of −38.83 °C and a boiling point of 356.73 °C, both the lowest of any 
metal. Mercury was found in environment as metallic Hg(0), inorganic (Hg(I), Hg(II)) 
(mainly HgS) in nature, and organic short-chain alkyl- mercurials (methyl, ethyl, etc.) by 
human pollution [34]. 
 
 
Mercury in the periodic table 
 
 
2.2.2 Isotopes of mercury 
There are seven stable isotopes (Table 2.2) of mercury (80Hg), which could be easily 
found from mass spectrum of the mercury complex [35], which 202Hg being the most 
abundant (29.86%). These stable mercury isotopes are mainly used to study mercury 
deposition and emissions on terrestrial and aquatic ecosystems. 
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Nuclide 
symbol 
Z(p) N(n) Accurate mass 
Natural 
abundance % 
Chemical form 
Enrichment 
available % 
196Hg 80 116 195.965807 (5) 0.15 (1) metal 30-52 
198Hg 80 118 197.966743 (4) 9.97 (20) metal 91+ 
199Hg 80 119 198.968254 (4) 16.84 (22) 
metal, oxide, 
sulphate 
65-91+ 
200Hg 80 120 199.968300 (4) 23.10 (19) 
metal, oxide, 
chloride 
77-98+ 
201Hg 80 121 200.970277 (4) 13.18 (9) metal 84 
202Hg 80 122 201.970617 (4) 29.86 (26) 
metal, oxide, 
chloride 
90-99+ 
204Hg 80 124 203.973467 (5) 6.87 (15) oxide 42-58+ 
 
Table 2.2: Stable isotopes of mercury (Trace Sciences International) 
 
An excerpt from the list of main radioisotopes of mercury is seen in table 2.3. Among all 
these isotopes, the longest-lived radioisotopes are 194Hg with a half-life of 444 years, 
and 203Hg with a half-life of 46.6 days. Most of the remaining 32 radioisotopes have 
half-lives that are less than a day. Among these radioisotopes, 197(m)Hg stand out as the 
most suitable radionuclides for theranostics studies owing to the promising physical 
characteristics (suitable energy and half-life) using current SPECT scanning devices. 
 
Nuclide 
symbol 
 
Z(p) 
 
N(n) 
 
Isotopic mass (u) Half-life 
decay 
mode(s) 
Daughter 
isotope(s) 
Nuclear 
spin 
Excitation energy 
 
192Hg 
 
80 
 
112 
 
191.96563(17) 
 
4.85(20) h 
EC 192Au  
0+ α 188Pt 
193Hg 80 113 192.96666(17) 3.80(15) h β+ 193Au 3/2− 
193mHg 
 
140.76(5) keV 
 
11.8(2) h 
β+ (92.9%) 193Au  
13/2+ IT (7.1%) 193Hg 
194Hg 80 114 193.96543(13) 444(77) y EC 194Au 0+ 
195Hg 80 115 194.96672(25) 10.53(3) h β+ 195Au 1/2− 
 
195mHg 
 
176.07(4) keV 
 
41.6(8) h 
IT (54.2%) 195Hg  
13/2+ β+ (45.8%) 195Au 
197Hg 80 117 196.96721(3) 64.14(5) h EC 197Au 1/2− 
 
197mHg 
 
298.93(8) keV 
 
23.8(1) h 
IT (91.4%) 197Hg  
13/2+ EC (8.6%) 197Au 
199mHg 532.48(10) keV 
42.66(8) 
min 
IT 199Hg 13/2+ 
201mHg 766.22(15) keV 94(3) µs   13/2+ 
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203Hg 80 123 202.97287(18) 46.595(6) d β− 203Tl 5/2− 
203mHg 933.14(23) keV 24(4) µs   (13/2+) 
205Hg 80 125 204.97607(4) 5.14(9) min β− 205Tl 1/2− 
205mHg 1556.40(17) keV 1.09(4) ms IT 205Hg 13/2+ 
206Hg 80 126 205.97751(22) 
8.15(10) 
min 
β− 206Tl 0+ 
207Hg 80 127 206.98259(16) 2.9(2) min β− 207Tl (9/2+) 
208Hg 80 128 207.98594(32) 42(5) min β− 208Tl 0+ 
 
Table 2.3: Main radioisotopes of mercury 
 
For the long time being, the applications given the chemical properties of 197Hg 
labeled compounds was not remarkable. The application in environmental studies was 
the only remaining usage for mercury radioisotopes (197Hg included) in the last few 
years [13, 14, 36, 37]. Specifically, mercury tracers were used to study mercury 
transformations in environmental systems, particularly mercury methylation, 
demethylation and reduction in sediments and water. These studies were given the 
potential for the isotopically enriched species to facilitate the study of 197Hg ions 
speciation and reactivity.  
 
2.2.3 Production of the radiomercury isotopes (203Hg and 197(m)Hg) for potential 
medical uses 
In the early studies, medical radiomercury (203Hg and 197Hg) were produced by the 
neutron irradiation in many different nuclear reactors [38-40]. The enriched 196Hg and 
202Hg was used for irradiations and became reasonably active by neutron capture to 
produce 203Hg and 197Hg via 196Hg (n,γ)197Hg reaction and 202Hg (n,γ)203Hg reaction. 
The main process is simply summarized as sample preparation and irradiation. 
Because of the volatility of the mercury compounds, the samples must be sealed in 
quartz tubes (silica tubes) before the irradiation can be performed. The tubes must be 
carefully cleaned before inserting the samples, and precautions taken to avoid 
contamination inside the tubes. The samples were irradiated in the nuclear reactor for 
1~2 weeks. In breaking the tubes after irradiation, precautions must be taken to avoid 
loss of gaseous radiomercury formed by the heat in the reactor. After careful cleaning 
of the tube to remove surface contamination, it is inserted in another sealed tube for 
the next studies [39]. For analytical studies, 197Hg and/or 203Hg are determined by γ-
spectrometry [38]  after the neutron irradiation. To avoid the peak of other contents, the 
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samples were left for at least 10 hours to let short-lived activities decay (especially for 
203Hg). 
 
The early use of 197Hg (details in 2.3) was limited by impurities, such as large 203Hg 
contamination, owing to the enrichment of 196Hg. That is due to the unique available 
routine of 197Hg production was through nuclear reactor in the past.  
With the development of cyclotron production techniques, low energy cyclotron could 
be used to produce the 197mHg and 197gHg isomers by the reaction of proton with gold. 
Target preparation and irradiation are the main process of production. According to the 
work of Elmaghraby et al. [15], the targeted was prepared with high purity gold foils of 
purity (99.999%) and thickness 10 mm provided from Good Fellow Company were 
used for studying the proton induced reactions on Au. The irradiations have been done 
using MGC-20 cyclotron in Inshas, Egypt. The irradiation by proton beam produced 
from the cyclotron continued for 1~2 h to obtain a detectable radioactivity. Beam 
current was always kept low (0.15~0.25 μA), to avoid target losses, it was necessary to 
apply an extra cooling to keep the temperature of the target as low as possible. 
 
For purity considerations, the applied proton energy EP should be limited in the 
production of medically radionuclides. S. Mandal et al. [15, 16] estimated the cross 
section for the formation of the radionuclides given in the Table 2.4 using the nuclear 
model code ALICE-91.  With the increasing of proton energy, the cross-section value of 
196Hg was also increased. A higher cross section for the formation of 196Hg was found to 
be about 727 mb at 15 MeV projectile energy, which is more than 2 time higher than at 
12 MeV group with no obvious increasing for the formation of desired 197Hg. Therefore, 
the applied proton energy EP was limited to 12 MeV to ensure high specific activity (As). 
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Table 2.4:The estimated cross-section of the radionuclides produced through 197Au+ p reaction using 
nuclear model code ALICE-91 [15, 16]. 
 
In the meantime, the theoretical [17] and experimental [41] studies of 
197Au(d,2n)197(m)Hg reaction showed great potential on 197mHg and 197gHg production, 
especially for the preferred 197mHg. Briefly, thin Au target foils (10.7 and 23.1 μm thick) 
with Al (100 μm thick) or Ti (12 μm thick) monitor foils were stacked and irradiated at 
the cyclotrons of CYRIC (Japan) and VUB (Belgium) with 40 MeV, 24 nA deuteron 
beam for 30 min and with 20 MeV, 185 nA deuteron beam for 54 min. All of their works 
showed high cross-section value of 197mHg and 197gHg. 
 
Besides, the 197(m)Hg isomers can also be produced by natPt (3He,xn)197(m)Hg or natPt 
(α,xn)197(m)Hg reactions on platinum [42, 43]. However, the cyclone(s) for α or 3He-
induced reactions are not available in this work and totally different mechanisms in 
separation of Hg/Pt are needed, these pathways were not considered.  
 
2.2.4 Major decay processes of 197(m)Hg: promising for theranostics  
Knowing the radioactive decay process helps us to know whether the emitted particles 
of radioactive mercury is suitable for theranostic studies. Thus, a visual representation of 
197(m)Hg radioactive decay [44] was given (Figure 2.2), 197mHg and 197Hg are presented 
separately as follows: 
 
197mHg has a half-life of 23.8 h. It is the isomeric state of 197Hg.The majority of 197mHg 
(91.4%) decays by isomeric transition to the ground state 197Hg, which is radioactive 
too.  Conversion electrons with an energy of 82 keV (20%), 119 keV (33%) and 150 
keV (50%) are emitted per decay. Additionally, photons with energies of 134 keV (34%) 
are emitted. The minority of 197mHg (8.6%) decays by electron capture directly to 
excited state 197Au. Conversion electrons with an energy of 116 keV (6%) are emitted 
per decay. Additionally, photons with energies of 134 keV (34%) and 279 keV (6%) are 
emitted. Following this, the excited state 197Au will decays by isomeric transition 
accompanied by photon and electron emission to stable 197Au. 
 
197Hg has a half-life of 64.1 h and decays to an excited state of 197Au (7.7s) by electron 
capture.  The excited state of 197Au eventually decays by isomeric transition to stable 
197Au, conversion electrons with an energy of 63 keV (60%) and photons with an 
energy of 77 keV (19%) are emitted. Because of the change in the electron shell 
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concomitantly X-rays (110%) with energies around 70 keV and Auger electrons (119%) 
with energies around 7.5 keV are released.  
Therefore, the board emission spectrum of 197(m)Hg decay and disexcitation processes 
shows great potentials of these radionuclides for the applications of for theranostic 
(imaging and therapy) purposes. In previous studies, the imaging properties of 197(m)Hg 
were evaluated using a Philips BrightView SPECT camera either [45]. 
 
 
Figure 2.2: Decay and de-excitation scheme of 197(m)Hg shows high potential for imaging and therapy [44]. 
 
These dosimetric properties are important for the therapeutic application of 197(m)Hg to 
get a high dose to the desired location. Among the emitted conversion electrons of 
197(m)Hg, the mono-energetic highest energy is 150 keV. While compared with a 
commonly used theranostics radionuclide 177Lu emittes a maximum beta energy of 498 
keV (the mean energy is 134 keV). Those energies correspond to a maximum electron 
range of 1.8 mm for 177Lu and 0.3 mm for 197(m)Hg. Therefore, both radionuclides are 
capable for the treatment of small lesions with a few millimeters in diameter. Owing to 
the higher number of Auger electrons from 197(m)Hg (190%), the dose per decay from 
197(m)Hg is ten times higher than the dose from 177Lu inside a sphere with 1 µm in 
radius. The higher dose of 197(m)Hg in a small volume should yield in higher therapeutic 
effectiveness compared to the pure beta-emitter [46]. Figure 2.3 shows the dose-point-
kernels for both radionuclides. Beyond the distance corresponding to the maximum 
electron range the dose deposition is caused by photons. For 197(m)Hg the gamma-dose 
is almost 6 times higher due to the higher number of emitted photons compared to 
177Lu but still much lower in comparison to the gamma-dose of clinical used 131I. In 
clinical therapeutical applications of 197(m)Hg, the dose should be considered carefully 
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considering its contribution to surrounding normal tissue. 
 
Figure 2.3: Auger- and conversion electrons for therapy 197(m)Hg beta-dose/range comparable to 177Lu [44]. 
 
 
2.2.5 Chemical properties of Hg and applications 
Unlike the rather similar chemical properties of Zn and Cd in group 12, Hg is somewhat 
quite distinct [47]. Mercury is undoubtedly having a much greater tendency to covalent 
bond and forms complexes whose stability is rarely exceeded by those of any other 
divalent cation. Mercury exists in the two main oxidation states, I and II. Mercury does 
not react with most acids, such as dilute sulfuric acid, while aqua regia would dissolve it 
to give nitrate and chloride. 
 
For instance, mercury(II) chloride (HgCl2) is the most important mercury salts, which is 
used as an insecticide, in rat poison, as a disinfectant and occasionally used to form an 
amalgam with metals, such as aluminum. Mercury(I) chloride, a colorless solid also 
known as calomel, is really the compound with the formula Hg2Cl2, with the connectivity 
Cl-Hg-Hg-Cl. It is used as a standard in electrochemical measurements and in 
medicine as a purgative in the past. Besides, mercuric oxide is formerly used in skin 
ointments; mercury fulminate Hg(NCO)2, a detonator used in explosives; mercuric 
sulphide (HgS) also called vermillion, a high-grade paint pigment; mercuric sulphate 
(HgSO4) is used as a catalyst in organic chemistry.  The organic mercury compounds 
thimerosal and merbromin are used mostly in medical products as preservatives.  
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Figure 2.4: Applications of natHg compounds as a preservative or antiseptic. 
 
 
2.2.6 Hg chemistry: organometallic compounds  
Apart from these most commonly applications of Hg mentioned earlier, the three forms 
of existed mercury (elemental mercury, inorganic mercury compounds, and organic 
mercury compounds) were formed numerous mercury compounds. Mercury(II) is able 
to form Hg-N, Hg-O, Hg-S and Hg-C bond compounds. Among all these complexes, 
organometallic compounds of mercury are the most interesting.  It refers to chemical 
compounds containing at least one chemical bond (covalent bond) between a carbon 
atom and mercury which called organomercury or organomercuric. Organomercury 
compounds can be characterized chemically by the covalent binding of one or two 
alkyl- or aryl- groups and covalent or ionic binding of a group such as halide, hydroxide, 
acetate, nitrate or phosphate to the mercury atom. The solubility, which is decisive for 
the effects of organomercury compounds in the organism, is determined not only by the 
degree of alkyl- or aryl- substitution and the structure of the organic groups but also by 
the kind of binding to the inorganic group. Generally, seven subclasses are often being 
covered in Hg(II) organometallics, including: organomercury hydrides, arylmercury 
compounds, alk-1-ynyl- and vinylmercury compounds, allylmercury compounds, β- and 
γ-heterosubstituted alkylmercury compounds, oxymercury and alkylmercury 
compounds. Historically, Dimroth’s discovery of electrophilic substitution of aromatic 
compounds by mercury(II) salts renewed interest in organometallic compounds of 
mercury [48]. Therefore, arylmercury compounds show great potential for the 
radiopharmaceutical applications among these subclasses owing to the stabilized 
binding system in aromatics. Table 2.5 lists several typical reactions for arylmercury 
compounds.  
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1.Electrophilic Substitution by Mercury(II) Salts [49] 
 
2.Mercury substitution of Arenediazonium Salts [50] 
 
3.Elimination of SO2 [51] 
 
4.Decarboxylation of Arenecarboxylates [52] 
 
5.Trihalomethyl Anion Addition to Arylmercury(II) Compounds [53] 
 
 
Table 2.5: Several typical reactions for arylmercury compounds. 
 
Although the chemistry of mercury has been extensively studied, the following great 
amount of mercury compounds didn’t provide us recorded compounds with highly 
stable Hg-C bond, especially for medical applications. Some of the typical reactions 
give us valuable information for the designation of precursors (ligands) for 197(m)Hg 
labeling. Nowadays, in the field of Hg organometallic chemistry, the widest range of 
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structural and functionalized moieties linked to mercury occurs with tin and silicon 
which could be classified and discussed in the next section in details. 
 
 
2.2.7 Hg-organometallics: the electrophilic aromatic substitution with trialkyltin-
precursors 
Electrophilic aromatic substitution is a very typical organic reaction in which an atom 
(e.g. hydrogen) attached to an aromatic system replaced by an electrophile. This is a 
very useful method for adding substituents to an aromatic system. Among a variety of 
electrophilic aromatic substitution patterns, a special case named Ipso (‘self’) 
substitution is an important case of electrophilic aromatic substitution. Ipso substitution 
expresses that two substituents occupy the same place in the ring.  
 
Mercury complexes have been commonly employed as electrophiles in the 
organometallic processes of electrophilic aromatic substitution or further said as Ipso 
substitution. There are two general types involving replacement of a substituent group 
in preference to hydrogen, which are the substitution of arylsilanes and substitution of 
arylstannanes. In aromatics substituted by silicon, the silyl group directs electrophiles 
to the substituted position. Trialkyltin substituents are also powerful ipso-directing 
groups which has been observed in a number of circumstances. The overall electronic 
effects are similar to those in silanes but the tin substituent is more metallic and less 
electronegative. The electron density at carbon is increased, as is the stabilization of ß-
carbocation character. The substitution with trialkyltin-benzoyl derivatives was also 
named as “mercuridestannylation” or “electrophilic mercurations”. Figure 2.5a 
elucidates the mechanism of electrophilic mercurations. 
The trialkyltin-phenyl-derivatives belong to a general class of organometals in which 
the ionization occurs from highest occupied molecular orbital (HOMO) which has σ-
bonding character; that is, they are donors. The electron acceptor properties of a series 
of mercury complexes were examined with these basically types of electron donors, 
like mercury iodide [54] and mercury chloride [55, 56]. The trialkyltin precursors provide 
us new approach for 197(m)Hg labeling incorporating Hg-C bond. 
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Figure 2.5a: Mechanism of electrophilic mercurations [54]. 
 
 
Figure 2.5b: Examples of electrophilic mercurations with mercury iodide [54] and mercury chloride [55, 56] 
 
Furthermore, the trialkyltin-precursors are important for synthetic purposes. There are 
varieties of trialkyltin-precursors have been well applied for labeling studies: like the 
labeling of 18F [57],76Br [58],123I [59] and 11CO2 [60]. These labelings proceed well even 
when very small quantities of trialkyltin-precursors are performed with radionuclides 
high specific activity, and the labeled molecules have been used for cell binding and 
animal studies (Figure 2.6).  
 
 
 
Figure 2.6: Radiolabeling of 18F, 76Br, 123I or 11CO2 [57-59] [60] with trialkyltin-precursors. 
  
Therefore, it might probably show great potential in the radio-labeling with n.c.a.197(m)Hg 
together with very small quantities of well applied precursors. However, there is an 
increasing need to understand more effectively radiosynthesis strategies, including 
more advanced approaches of chelating units and subsequent stability studies. In 
addition, some variations of trialkyl- groups will increase the rate of reaction (activating) 
while others will decrease the rate (deactivating).  
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2.2.8 Chemical behavior of mercury: Hg(II)-ion selective chemosensors 
Considering the Hg pollution and accumulate in the environment, there is a growing 
demand for sensitive and selective detection of mercury contaminants in the 
environment and food industry these years. Given that, the development of sensors for 
mercury detection has received significant attention. There are vast numbers of 
sensors which were classified into several different categories, such as small molecule 
based sensors, calixarene based chemosensors, polymer based chemosensors, DNA 
and protein functionalized sensors, and nanoparticle based sensing systems. Here 
listed some of the binding site of developed Hg2+ selective sensors: 
  
A chemosensor containing Nitrogen-Sulfur binding moiety (NS2) for the reversible 
binding receptor of Hg2+ in aqueous media was introduced by Qian et al. [61]. The 
assumed chelating structure is shown in Figure 2.7a.  A sensor containing a thiol-crown 
cage-like group as the binding moiety was synthesized by Ho and Chou et al. [62] 
(assumed structure Figure 2.7b). The sensing site of these chemosensor were omitted. 
Besides, series of Hg2+ selective DNA thymine sensors were developed [63, 64].  Since 
a Hg2+ ion can specifically bind in between two DNA thymine (T) (Figure 2.7c). The 
binding of Hg2+ ions by T-T pairs is strong and highly selective. These duplexes that 
contain a T-T pair are thermally stabilized in the presence of Hg2+ ions; in the 
meanwhile, other heavy-metal ions do not show any notable effects on duplex stability 
[65]. But with the further investigation, it was clearly reported that the binding of 
cysteine-Hg-cysteine shows higher stability than T-Hg-T (N-Hg-N bond), which 
indicated the unavailable of exploiting T-Hg-T for medical application [66]. An reversible 
Hg2+ sensor (Figure 2.7d)  was reported which composed of a thiol atom and an alkene 
moiety, the S atom and the alkene moiety of the compound took part in the 1:1 
stoichiometry binding with Hg2+ and the binding is reversible when excess EDTA was 
added under the neutral conditions [67]. 
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Figure 2.7: Several proposed binding modes of Hg(II) ions in chemosensors. (a): Hg-NS2 complex [61], (b): 
Hg-thiol-crown complex [62], (c): T-Hg-T DNA based complex [63, 64], (d): Hg reversible binding [67]. 
 
These reported sensors have strong sensitivity and high selectivity to avoid the severe 
interference of ‘foreign’ metal ions, and are compatible with aqueous environments 
which shows relative solubility.  
While, the medical uses of 197(m)Hg-complexes have more vigorous conditions (solubility 
included) than the environmental or analytical studies. The lacking of knowledge on no 
carrier added 197(m)Hg labeling studies, requires completely new thinking to develop 
new suitable ligands for medical application, these reported sensors inspired us for 
promising strategies of chelator (ligand) designation. 
 
 
2.2.9 The toxicology of mercury 
Mercury is ubiquitous in the environment. The element and its compounds are released 
into the environment by volcanic eruptions, earthquakes, and industrials, etc. The 
situation is disastrous follows the worldwide applications of mercury containing 
chemicals [68]. On the one hand, mercury has many attractive and useful properties, 
on the other hand it presents a risk of toxic effects either. If we want to do further 
studies of Hg radiopharmaceuticals, further knowledge is needed about toxicity of 
mercury. 
 
The toxicity of mercury depends on the dose and chemical forms of mercury. A famous 
physician popularly known as Paracelsus, observed that high doses of mercury 
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poisoned his patients and made the immortal pronouncement that ‘‘the dose makes the 
poison’’ [69], which have been the fundamental principle in the science of toxicology. 
Like any other element, toxicity is increasing with the dose of mercury increasing. The 
toxicity of mercury primarily depends on its chemical form. Normally, metallic mercury 
and HgS are the least toxic, because they are not reactive. The toxicity is basically 
increasing from inorganic to organic forms of mercury.  
 
2.2.9.1 The toxicology of inorganic mercury 
Among inorganic mercury salts, the mercuric cation, Hg2+, is believed to be the 
proximate toxic agent for all these inorganic forms of mercury.  The toxicity has great 
influences on kidneys and decreases by sinking water solubility, that is lowered 
gastrointestinal absorption, which appeals in the following order: 
Hg(NO3)2>HgCl2>HgSO4>Hg2Cl2 >HgO (HgCl2 mostly accumulated in kidneys). 
Mercury(II) is subsequently reabsorbed into the renal cells as a complex with one of 
these products, probably the mercury-cysteine complex, possibly via the large neutral 
amino acid transporter [70]. Cells contain many binding sites for mercury, such as the 
ubiquitous -SH ligands. The body fluids, on the other hand, usually contains few 
mercury binding sites. Consequently, mercury rapidly leaves the incubation medium to 
attach to cellular components. How much binds to the cell depends on the ratio of the 
number of cells to the volume of the media [71]. 
 
Intake of mercury by infection and inhalation: relatively little mercury in inorganic form 
crosses the blood brain barrier; most is excreted in the urine or feces, or is retained by 
the kidneys. However, inorganic mercury can be formed in the brain as a metabolite of 
other forms of mercury. Fecal excretion accounting for 50% of total elimination was 
dominant after the first week after intoxication. In long-term occupational exposures, 
urinary excretion becomes dominant [72]. The reduced glutathione (GSH) also plays an 
important role in the renal handling of mercury (Figure 2.8). Presumably, thiol ligands of 
two glutathione molecules attaches the mercuric cation to form a structure that 
resembles that of oxidized glutathione (Figure 2.8) and is exported from the liver cells 
on glutathione carriers.  
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Figure 2.8: GSH connection of inorganic mercury, Hg2+ attaches to the thiol ligands of two reduced 
glutathione molecules to form a complex. 
 
 
2.2.9.2 The toxicology of organic mercury 
The organic mercury species are more toxic than insoluble inorganic mercury salts 
which is mostly because it would transport across the blood-brain barrier and the 
primary target is the central nervous system. Methylmercury (cation), ethylmercury 
(cation) are the main sources of organic mercury that human exposures, the methyl- 
and ethylmercury compounds have similar chemical properties and are often referred 
to as the “short-chain alkyl- mercurials.” Besides, less than 10% human exposure of 
other organomercurials are phenylmercury and methoxyethylmercury compounds. 
 
Intake of mercury by infection and inhalation: relative little of methyl- and ethylmercury 
compounds (organic mercury) are excreted in the urine which are clearly different from 
inorganic mercury. The methylmercury-cysteine accounts for less than 1% of 
methylmercury in whole blood. Most mercury is bound to the hemoglobin in red cells, 
with a small fraction attached to glutathione. Of the small fraction found in plasma, 
most is protein bound [73]. In contrast, methylmercury appears to exclusively damage 
the central nervous system, at least in primates. The intact organomercurial cation is 
believed to be the proximate toxic agent responsible for damage to the central nervous 
system. Methoxyethylmercury is rapidly converted to inorganic mercury so that their 
toxic effects are similar to those inorganic mercury compounds. However, it is more 
efficiently absorbed into the body than inorganic mercury.  
 
Generally speaking, most health authorities carefully regulate human exposure to all 
forms of mercury. For humans, the average daily Hg intake is ~6.6 µg (ca. 10% as 
organic mercury). The maximum consumption limit for Hg is 300 μg per week, with a 
maximum of 200 μg methylmercury (cation), according to the World Health 
Organization [74]. The consumption of organic mercury is obviously more dangerous. 
The toxic level for organic mercury compounds in blood is >50 ng/ml [71]. 
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196Hg with thermal neutrons for the 196Hg (n,γ)197Hg reaction generates 197Hg with lower 
specific activity and the occurrence of the long lived radio contaminant 203Hg through 
thermal neutron capture in 202Hg. These drawbacks about high toxicity and long 
biological half-life limited the use of 197Hg-Chlormerodrin by 196Hg (n,γ) 197Hg reaction in 
vivo. Finally, with the improvement of cyclotron produced 197Hg, this contamination has 
been minimized.  It is still lack of report about in vivo or in vitro stability studies of 
radiolabeled chlormerodin, which could be quite critical. The exact reason of 
decomposition (weak stability) is probably because of the demetalation of 197Hg-
Chlormerodrin. The mechanism of solvomercuration and demercuration is shown in 
Figure 2.10: 
 
 
 
Figure 2.10: Solvomercuration and demercuration process of alkylmercury 
 
Many reported literatures [80-82] and our studies (supplemental Figure 1) showed that 
the solvomercuration is a reversible reaction. The demercuration process is a kind of β-
elimination reaction, which is a spontaneous process. The reverse reaction occurs 
slowly until chemical equilibrium or rapidly with the presence of thiols. Owing to the 
followed demercuration related so tightly, it is hard to avoid the demetalation process. 
Therefore, the degradation of 197Hg labeled Chlormerodrin and related 
solvomercurations further demonstrate that they are not suitable as 
radiopharmaceuticals. 
 
Another important reason for the unpopular of 197Hg labeled Chlormerodrin is the 
development of 99mTc tracers. In 1960, Richards became the first to suggest the idea of 
using technetium as a medical tracer [83]. With the development and continuous 
improvements of the 99Mo/99mTc generator and gamma camera, the production and 
medical use of 99mTc rapidly expanded in the 1960s, numerous scientific studies 
demonstrated the use of 99mTc as radiotracer [84, 85]. With the replacement of mercury 
isotopes labeled tracers by 99mTc tracers, the investigations with radiomercury labeled 
compounds were finished. 
 
Considering the clinical studies with 197Hg labeled chlormerodrin were promising but 
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with obvious shortcoming. Some scientists believe that free mercury chloride could 
proposed mercuric dichloride ([197Hg]HgCl2) and the results would suggest that it is 
more suitable than 197Hg labeled Chlormerodrin [81]. Unlabeled [197Hg]HgCl2 (mercuric 
dichloride) was used in the diagnosis of several cases of carcinoma. Their results 
showed that free HgCl2 is not in practice as a sufficiently sure method of diagnosing.  
 
 
2.3.3 197(m)Hg labeled bio-molecules based on Hg-S bond in the past 
2.3.3.1 Labeling Fibrinogen with 197Hg (Protein labeling) 
Hg2+ ions could form chelates with free thiols of almost all bio-molecules. Given this, in 
the early time, preparation of radioactive mercury labeled proteins are based on this, 
also called 197Hg-proteinate. Sara et al. [86] performed a method about labeling of 
human fibrinogen with [197Hg]HgCl2, which showed great potential of clinical usefulness 
as a suitable agent for the detection of thrombi. Fibrinogen is a glycoprotein 
in vertebrates that helps in the formation of blood clots. A maximum yield of 90~95% 
was obtained by incubating 10 mg of fibrinogen with 197Hg at pH 7.4 and at room 
temperature for 30 min. Radiochemical purity was not displayed. Short incubation time 
with mild temperature guarantees the intact structures of the proteins. Their research 
suffered from the lack of in vivo and in vitro stability studies about labeling products and 
most importantly, excretion behavior in bodies. But the weak Hg-S binding, will be 
easily challenged by other thiols in human body, for instance glutathione. 
 
With a given concentration of fibrinogen, due to the presence of non-radioactive 
mercury in 197Hg radionuclides, labeling yield can’t be increased simply by adding 
increasing volume of 197Hg from stock solution of a known specific activity. So, higher 
specific activity 197Hg is needed in order to obtain higher yield of labeled fibrinogen.  
 
2.3.3.2 Labeling Human Albumin Microspheres with 197Hg (protein particles labeling) 
In 1980, R. J. Callahan et al. investigated if human albumin microspheres could be 
labeled with197Hg [87]. The labeling procedure was the same as other literatures. 
Moreover, they did biodistribution studies, the labeling products at 10 min, 60 min and 
180 min in mice. However, result show that the concentration of radioactivity in blood, 
kidneys and carcass is not significantly different (p > 0.05) for the microsphere and 
conjugated with rabbit IgG 
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incorporating the soft macrocyclic ligand cyclononane-active ester  [91]. This ligand 
was pre-chelated with 197Hg, then the chelate was conjugated with rabbit IgG 
(reference antigen, standard agent, or coating protein) via an active ester to give 
material for chromatographic investigations. Most (52~93%) of the radioactivity in the 
protein fractions. This patent did not show more in details. 
 
 
 
Figure 2.12: Structure of macrocyclic thioether ligands [91]. 
 
In summary, almost all these early research articles are based on ‘simple’ Hg-S bond 
labeling strategies owing to the large presence of -SH and -S-S- in bio-molecules. 
Whereas the same presences of thiols in human blood and organs may have strong 
interference to tracer stability after administration. This is the main reason why the 
early studied 197Hg labeled tracers were not applicable for pre-clinical studies. The last 
example by which pre-chelation with 197Hg and afterwards conjugation with bio-
molecules via active ester provides new stable chelation patterns for 197Hg labeling. 
Therefore, novel bifunctional chelators or precursors are urgent needed for this 
improved strategy. 
 
 
 
2.4 Conclusion for the own investigation  
According to the overview of literatures survey, the imaging and theraputic potential of 
197(m)Hg is doubtless high for clinical applications. The major advantages of 197(m)Hg can 
be classified as four parts. Firstly, the promising decay properties for imaging and 
therapy: 197mHg 23.8 h/197Hg 64.14 h with emitted γ and Auger electrons, conversion 
electrons and natgold as decay product. Secondly, n.c.a. available from natGold using a 
cyclotron. Thirdly, exceptional labeling chemistry as metal: chemically stable Hg 
compounds in water. Lastly, low average crustal abundance of mercury with 0.08 ppm, 
water 0.01-10 ppb makes high specific activity possible.  
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For theranostics studies, the toxicity of 197(m)Hg shows clearly difference according to 
the varies of production approaches. The presumed activity for imaging was set to 50 
MBq and therapeutical doses 5 GBq (from the 177Lu studies). Considering 197(m)Hg 
nuclear reactor based production via 196Hg (n,γ)197Hg reaction displayed low molar 
activity (~1 GBq/µmol), the imaging activity would be correlate to 50 nmol (10 µg) with 
approximately 2 ng/ml in around 5 L human blood. The theraputical dose would be 
correlate to ~5 µmol (1 mg Hg) and the concentration of 197(m)Hg-complex would reach 
upto 200 ng/ml in around 5 L human blood which is exceed the toxic level.  
The cyclotron produced 197(m)Hg is per definition no carrier added (n.c.a.). Thus, 
n.c.a.197(m)Hg produced by (p,n) or (d,2n) reaction displays high molar activity ( 1000 
GBq/µmol). The imaging activity correlate to 0.05 nmol (10 ng) with approximately 0.02 
ng/ml concentration in human blood. The therapeutical dose correlate to ~5 nmol (1 µg 
Hg) with approximately 0.2 ng/ml concentration. Accordingly, the direct health risks 
from 197(m)Hg labeling compounds is rather low. 
 
Looking back on the previous approaches, nearly all studies suffered from the problem 
of non-availability of n.c.a. 197(m)Hg. The carrier added 197(m)Hg was not only easy to 
exceed the toxic amount for human, but also affect the quality of labeling (low chemical 
purity and radiochemical purity), which caused the low progress of 197(m)Hg for clinical 
applications in the past. Additionally, the unsuccessful outcomes are also because of 
the weak stability of 197(m)Hg labeled compounds. It forces us developing new chemistry 
to improve the quality and usability for molecular imaging and radionuclide therapy. 
 
The summarized conditions precedent to develop new radiopharmaceuticals based on 
n.c.a. 197(m)Hg radioisotopes: Firstly, for 197(m)Hg labeled compounds, the chemical bond 
between the 197(m)Hg atom and the chelating molecule must be stable. The radioactive 
signal (absolute concentration of 197(m)Hg-complex) within target should be high. For 
labeled substances, the target-to-brain, target-to-blood and target-to-muscle 
concentration ratios should be as large as possible. Besides, the biodistribution of the 
197(m)Hg labeled compounds throughout the body should not become highly 
concentrated and retained in a particular organ or group of organs, to avoid unwanted 
doses. For optimal nuclear medicine application, relatively large amounts of 
radioactivity have to be administered and satisfactory concentration of the radioactive 
mercury labeled compound within target organ must be maintained for a sufficient time. 
From this follows that complicate evaluations must be performed before a novel 
197(m)Hg-complex is introduced for clinical studies. Since different chelators or ligands 
have different coordination abilities with 197(m)Hg, affecting the accumulation of different 
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197(m)Hg chelating units which eventually influence the biological behaviors. 
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3 Results and discussions 
3.1 Radionuclide production of 197(m)Hg 
Two different reactions were applied in our investigations for the no-carrier-added 
197(m)Hg production from gold, via the 197Au(p,n)197(m)Hg reaction or the 
197Au(d,2n)197(m)Hg reaction. 
 
3.1.1 197Au(p,n)197(m)Hg reaction 
The target setup consists of a gold foil wrapped in aluminum. A gold foil (10 mm 
diameter, 125 μm in thickness, and 172~186 mg in weight) in an adopted aluminum 
holder can be easily disassembled and dissolved completely after irradiation. The 
content of the stable mercury isotope 202Hg originated from the gold target was very low 
(measured by ICP-MS). Irradiations were performed at a Cyclone 18/9 cyclotron 
(IBA/Belgium) at Helmholtz-Zentrum Dresden-Rossendorf with a short beamline. The 
gold foils were irradiated for 2~2.5 h with a 20~25 µA beam current of 10 or 12 MeV 
protons (depending on the cyclotron). The cyclotron is equipped with a home-made 
solid target holder and a remote ejecting system for solid targets, which facilitates 
radiation protection for the operators.  
The irradiation parameters are shown in Table 3.1 (No.1~4); the radioactivity yield was 
between 100~300 MBq of 197(m)Hg. For the exact activity determination, γ-ray 
spectroscopy measurements were performed. This is due to the produced isomeric 
mixture. One major side product 198Au, and two minor side products 194Au and 196Au 
were detected, respectively, in the unprocessed target solution. The content of the 
198Au in the product solution was used as an indicator of successful separation. 
 
The use of higher proton energies was excluded to avoid the production of 
predominantly stable 196Hg [16] ( ~ 315 mb at 12 MeV and 950 mb at 18 MeV for 
196Hg) and  to keep the specific activity of 197(m)Hg as high as possible.  Other 
parameters had to be optimized like beam intensity, target thickness (mass) and 
workup procedures in terms of minimization of product loss. The beam intensity for the 
targets is limited to 27 µA by the Cyclone 18/9 cyclotron (IBA/Belgium).  Besides, the 
ICP-MS measurement was performed to give an overview of the metal contents of 
products after decaying. As expected, non-radioactive 197Au was the major metal 
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content in most samples at a range of 12~34 µg per batch.  
 
3.1.2 197Au(d,2n)197(m)Hg reaction  
The target setup was the same as described earlier (3.1.1). Irradiations were 
performed on the external beam of U-120M cyclotron at the Nuclear Physics Institute of 
the CAS, Řež, Czech Republic (CAS: Czech Academy of Sciences). The gold foils 
were irradiated for 2~2.5 h with a beam current of ~10 µA with 16 MeV deuterons. The 
irradiation parameters and results of separation runs for 197(m)Hg are shown in Table 3.1 
(No.5, No.6), which results in a yield of over 800 MBq of 197(m)Hg. Different from proton 
induced 197Au(p,n)197(m)Hg reaction, 198Au of obviously higher activity was produced in 
the 197Au(d,p)198Au reaction (also 196Au to some extent). The content of the 198Au in the 
product solution was also used as an indicator of successful separation.  
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  E particle tirr IT mAu 
AEOB [MBq]  
in target solution 
YieldEOB [MBq/ µA·h] 
 in target solution 
AEOB [MBq] 
 in product solution 
Yield 
No   [h] [µA] [mg] 197Hg 197mHg 196Au 198Au 197Hg 197mHg 196Au 198Au 197Hg 197mHg 196Au 198Au   
1 10 MeV p 2 25 185 81 89 0.004 0.099 1.62 1.78 <0.001 0.002 75 83 <0.001 <0.001 93% 
2 12 MeV p 2.25 20 186 145 160 0.021 0.184 3.22 3.56 <0.001 0.004 136 150 <0.001 0.002 94% 
3 12 MeV p 2 20 186 121 134 0.024 0.157 3.02 3.35 <0.001 0.004 115 127 <0.001 <0.001 95% 
4 12 MeV p 2.25 20 186 163 223 0.049 0.184 3.62 4.96 0.001 0.004 151 207 <0.001 <0.001 93% 
5 16 MeV d 2 11 186 272 462 7 156 12.36 21 0.318 7.09 248 420 <0.003 <0.003 91% 
6 16 MeV d 2.5 10 186 332 574 9 193 13.28 22.96 0.36 7.72 315 545 <0.006 <0.003 95% 
 
Table 3.1: Irradiation parameters and results of the six production and separation runs for 197(m)Hg. Parameters: For 197Au(p,n)197(m)Hg, 2~2.5 h with a 20~25 µA beam current of 
10 or 12 MeV protons. For197Au(d,2n)197(m)Hg reaction, 2~2.5 h with a beam current of ~10 µA with 16 MeV deuterons. Half-life: 197mHg 23.8 h; 197Hg 64.1 h; 198Au 6.2 d; 198Au 
2.7 d. 
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In short, proton or deuteron irradiation can both be employed to routinely produce 
197(m)Hg in sufficient quantity and quality. However, 197(m)Hg produced by proton 
irradiation shows lower activity and lower percentage of isomeric state 197mHg, which is 
suitable for analytical studies and labeling studies in small scale. In contrast, deuteron 
irradiation is more suitable for animal studies and preclinical trials because of the high 
radioactivity yield of 197(m)Hg in a small volume.  
 
 
3.2 Radiochemical separation methods of 197(m)Hg from the gold target  
The separation of n.c.a.197(m)Hg from irradiated gold targets, is an essentially problem 
for application of this ‘new’ radionuclide before radiolabeling studies. A survey has been 
made on chemical separation of mercury, including distillation of the metal, extraction 
by organic solvents, and extraction by resin [16, 36, 44, 92-98]. However, due to 
different mechanisms, these techniques are not always satisfactory. Accordingly, an 
applicable separation method should fulfill following demands: separation efficiency, 
total processing time, purity and only one chemical form of n.c.a.197(m)Hg, possibility for 
the process automatization, redissolving of 197(m)Hg and adjusting the final volume of 
product. In this work, a reliable method for the radiochemical separation of 
n.c.a.197(m)Hg from gold target was needed to be developed.  
 
3.2.1 Commercial mercury chelating resin for 197(m)Hg separation 
A series of sulfur containing resin designed for the selective removal of mercury for 
industrial and environmental applications is available. Thus, these commercial Hg 
chelating resins took the lead for the separation studies. Purolite®S914 and 
Purolite®S920 (Purolite Deutschland GmbH) were chosen. 
 
Purolite® S914 is a macroporous type chelating resin with thiourea functionality. It has 
very high selectivity for mercury and is stable over the whole pH range. It was mainly 
used for mercury removal from brine and effluent in chloralkali process or from flue gas 
scrubber effluent. 
For our purposes, the irradiated gold plate was transferred into conical flask and 
dissolved in 0.7 ml aqua regia, 5 µl of fraction was taken out and dissolved in 50 µl 0.2 
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M HCl to test the possibility of separation. ~400 mg resin was loaded on the column. 
The column was rinsed with 50 ml 0.2 M HCl. Then, 5 MBq 197(m)Hg were loaded onto 
the column. Hydrochloric acid was used as the eluents, with an increasing 
concentration (0.2 M HCl, 0.5 M HCl and 1 M HCl).  With low concentration was carried 
out first with nearly no activity was collected. Then, changing to a higher concentration 
with very low activity was eluted. In the end, only 0.8 MBq of 197(m)Hg was washed out 
totally. Most of 197(m)Hg remained on the column. Measuring was done by dose 
calibrator (Isomed 2000, Dresden, Germany). 
 
Purolite® S920 is a macroporous polystyrenic based chelating resin, with thiouronium 
groups. It was designed for the selective removal of mercury either, especially for the 
removal of low concentrations of soluble mercury salts from waste streams and for the 
recovery of precious metals from rinse waters in the galvanic and electronic industries.  
Similar procedure was performed as described for and only 0.5 MBq 197(m)Hg were 
washed out from totally 6.5 MBq 197(m)Hg. 
 
The results show that commercial Hg chelating resin is not as effective as we expected 
for the separation. The radioactive mercury, in particular, is strongly bound to the 
functional groups of these two types resin to form highly stable complexes, with high 
selective affinity compared with those of other heavy metals. These properties are 
largely unaffected by high chloride or sulphate (Cl- or SO42-) content of the effluent.  
The Hg-resin bound are too strong, which causes the remaining of 197(m)Hg from the 
resin.  That is why these resins are only reported for environmental applications [99].  
Moreover, we haven’t considered that platinum group metals such as gold was reduced 
in the resin, which is another deadly drawback. Besides, comparing with Purolite® 
S914, Purolite S920 is more resistant to oxidation than many thiol-based resins. 
However, considering aqua regia is used to dissolve the target, strong oxidizing agents 
may still damage the resin. 
 
 
3.2.2 Separation by evaporation/distillation 
Heating is always a simple but effective way for separation. Distillation of mercury was 
the earliest proposed method for the radiochemical mercury separation from gold [93]. 
The boiling point of pure mercury is only 357 °C at 760 mm Hg-column, while pure gold 
is 3000 °C (Table 3.2). The large difference of boiling point between mercury and gold 
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3.2.3 Liquid-liquid extraction with methyl-isobutyl-ketone (MIBK) 
The early separation studies in this work were performed with n.c.a.197(m)Hg through 
liquid-liquid extraction (LLE) with methyl-isobutyl-ketone (MIBK). It was commonly used 
for the separation of metal ions (Au/Hg) based on their relative solubility in two different 
immiscible solvents. The procedure was performed as follows: 
 
The irradiated part of the gold foil was dissolved with 0.7 ml of aqua regia (525 µl 37% 
HCl + 175 µl 68% HNO3) at room temperature for ~ 50 min. The solution was then 
decanted into a 5-ml round flask (NS 14.5) for evaporation to dryness using a rotary 
evaporator. To avoid loss of activity the bath temperature was limited to 40°C and the 
pressure was carefully reduced stepwise from 100 mbar to 1 mbar. The yellow residue 
was redissolved in 500 µl 2 M HCl and remaining gold target material was extracted 
with 4 x 500 µl methyl-isobutyl-ketone (MIBK). Around 60% of radiomercury was 
extracted. This extraction fraction was dissolved in 2 M HCl which have to be 
evaporated to dryness again. The experiment was performed with following conditions: 
185 mg gold foil, 24 µA, Irradiation time 120 min.  
 
However, during the last step of evaporation, a high activity was lost by sublimation. 
The loss of activity was much obvious when the evaporating solution became nearly 
dry (Table 3.3), which urges us not only limiting the bath temperature and reducing 
pressure carefully, but also monitoring the activity remained several times (>2 times) 
before the final solution was dry completely.  
This last evaporation process remained as the unsolved problem for each separation. 
That forced us to attempted to avoid evaporation of [197(m)Hg]HgCl2, or make the 
combined step to avoid the loss of activity.  
 
Product status Evaporation Time Activity 
Before evaporate 0 min   (15:15) 176.8 MBq 
Roughly 50 µl 25 min (15:40) 165.9 MBq 
Roughly 10 µl 33 min (15:48) 160.5 MBq 
Nearly dry 36 min (15:51) 151.1 MBq 
Completely dry 37 min (15:52) 130.7 MBq 
 
Table 3.3: Activity left during last evaporation of [197(m)Hg]HgCl2 
 
In order to decrease the final volume of product, a simple approach was developed to 
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avoid the last time evaporation. The solubility of HgCl2 decreases from 36% in 100 °C 
to 6% at 20 °C in water. Given that, we attempted to reduce the temperature to make 
[197(m)Hg]HgCl2 precipitating (sticking) on the vessel. ~50 MBq [197(m)Hg]HgCl2 solution 
was taken into a 10 ml glass bottle and cooled by ice water for 10 min. Then solution 
was removed completely, the activity of the empty bottle was measured in a dose 
calibrator (Isomed 2000, Dresden, Germany). The activity sticking on the glass vial was 
only 1.4 MBq comparing to total activity 50.5 MBq. Same procedure was carried on dry 
ice (CO2) with the result of 0.7 MBq. The low activity indicated this method as an 
inconvenient alternative. 
 
 
3.2.4 Liquid-solid extraction with TEVA resin 
Firstly, we intended to find resin(s) with higher selectivity factor of desired Hg2+ than 
Au3+, which would be easier for monitoring the extraction process. For several resins 
(e.g. TEVA and LN resin) metal ions with higher charge (+3) are retained (high capacity 
factor), while metal ions with lower charge (+2) are passed (low capacity factor) in 
general. Eichrom TEVA Resin (TEtraValent Actinides) has been applied on a routine 
basis to the analysis of technetium, the determination of the tetravalent actinides, and 
the separation of americium from lanthanides. The active component of the TEVA 
Resin is an aliphatic quaternary amine (Figure 3.1). As such it performs similar 
properties to those of typical strong base anion exchange resins.  
 
 
 
Figure 3.1: Quaternary ammonium salt Aliquat® 336 
 
The irradiated gold foil was transferred into 700 µl aqua regia at room temperature. The 
gold was completely dissolved after 50-60 min. An Eppendorf pipette tip (10 ml) has 
been prepared for use as a column: The tip was filled with glass wool; the resin was 
placed on top and then fixed with a final layer of glass wool. TEVA Resin study were 
performed with 6 M HCl and 10 M HNO3 elutions separately.  
 
Experiment with 10 M HNO3:  Fresh TEVA Resin TE-200-A (100-150 µm) was soaked 
with 10 ml 10 M HNO3 in the beaker (5 minutes), then this suspension filled into the 
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Figure 3.3: Di(2-ethylhexyl)orthophosphoric acid (HDEHP) 
 
A currently extraction was described here as example, diagram of the assemble and 
operation process is seen in Figure 3.5: Irradiated gold foil (558.6 MBq) was 
transferred into a flask containing 700 µl aqua regia at room temperature. The gold was 
completely dissolved after 50-60 min. An Eppendorf pipette tip (10 ml) has been 
prepared for use as a column: The tip was filled with glass wool; Fresh LN resin (3.6 g) 
was incubated with 10 ml 6 M HCl in the beaker (5 min), then this suspension filled in 
the empty column; Then fixed with a final layer of glass wool. The column was rinsed 
with another 30 ml 6 M HCl to finish the column preparation. 
 
Extraction process: For accurate calculation of eluting volume, 300 µl 6 M HCl was 
added into the crude Au/Hg solution (700 µl), then this solution (1000 µl) was loaded 
onto the home-made column carefully. Rinse the empty flask with 1 ml of 6 M HCl and 
load this fraction on the column. Check the activity of the left empty flask to make sure 
197(m)Hg loaded completely. As seen in Figure 3.5, after loading the bright yellow mixture 
of chloroauric acid and no-carrier-added mercury chloride, the yellow gold solution was 
observed to rapidly distribute initially but then slow during the stepwise elution with 6 M 
HCl. The eluent was 1 ml for once in the beginning and then 500 µl. After the addition 
of ~51000 µl of HCl, the yellow chloroauric acid extended roughly two thirds of the 
way down the column and almost completely stopped moving. The activity of eluting 
fractions was measured separately in a dose calibrator (Isomed 2000, Dresden, 
Germany). No activity was eluted in the first 51000 µl of HCl. Then 3500 µl 6 M HCl 
fractions eluted with activity measured separately. Combine these low activity fractions 
as pre-product fraction 3.4 MBq. The majority of n.c.a.[197(m)Hg]HgCl2 (277.2 MBq) 
product solution was eluted in next two combined fractions of 2500 µl 6 M HCl. 
Additional product residues can be obtained by prolonged elution with further 2500 µl 
6 M HCl (213.2 MBq). At this time two main products were eluted. While, total 
calculated activity could be higher after separation than before, because of different 
volume and now absent shielding of Gold. Rinse the column with 6 M HCl until 197(m)Hg 
was eluted completely. Tail product (48.72 MBq) with 2500 µl 6 M HCl was eluted. 
Check the column’s activity to stop eluent with HCl. For the recycling of gold, the eluent 
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3.2.6 Summary  
Many different methods were applied for chemical separation of radiomercury, including 
distillation of the metal, extraction by organic solvents, and adsorption by resin. 
However, owing to the different mechanisms, these separations do not always give 
satisfactory results. Therefore, the developments of a simple, fast, efficient, application 
friendly separation technique was needed. Table 3.4 demonstrates the tested Hg/Au 
separation methods that have been applied after the 197(m)Hg production by irradiation. 
Although so many approaches have been applied, the use of LN resin was the most 
suitable approach. All the other candidates had more or less shortcomings. In order to 
make intuitive comparison between these separation methods, some methods that 
have not been tested are listed here as example: 
 
Metal distillation produced unusable amalgam or metallic Hg. An instrument for Hg 
distillation is shown in Figure 3.6. The target was placed at the bottom of a quartz tube, 
the target was heated and kept at a temperature ranging from 500°C to 600°C, being 
careful not to overheat. To avoid the escape of mercury vapor, the collection piece is a 
cooling finger inserted into the quartz tube, this part should be perfectly match [94].  
Some mercury deposit methods are also reported. For the recovery of mercury 
amalgamation with copper is needed. Copper will reduce mercury onto its surface from 
aqueous solution, Heating for 30 min was sufficient to distill all the mercury metal (not 
useable) deposited on the copper [93]. This was not tested. 
 
 
Figure 3.6: Optional instruments for Hg distillation. 
 
Liquid-liquid-Extraction (LLE) with MIBK was tested, initially. However, the long 
processing time might cause the operational mistakes and radiation exposure. The low 
efficiency of separation was unbearable after several times applications, which forced 
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us to look for further optimization and better alternatives. 
There are many alternative solvents for LLE separation other than MIBK, 
isoamylacetate was one of them. But several steps had to be combined in order to 
obtain satisfying radiochemical purity when extracted with isoamylacetate. 
Subsequently, mercury was extracted with dithizone in carbon tetrachloride in the 
proceeding separation and purification. A final precipitation step by SnCl2 resulted in a 
pure mercury sample suitable for the gamma spectrometric measurement. The 
chemical overall yield typically lies in the range of 30-50%. LLE with isoamylacetate 
showed lower efficiency and same drawbacks. Therefore, it was not tested. 
 
A novel LLE performed with Ionic liquid has been reported recently [97]. For our own 
investigations, Ionic liquid-salts were prepared with the composition of water soluble 
ionic liquid 1-butyl-3-methylimidazolium chloride ([bmim]Cl) and salts K3PO4, K2CO3. 
Gold target was first dissolved in aqua regia and then diluted with water to prepare a 
12ml solution. Two different ionic liquid sets were prepared and both applied available 
for the separation. In one set, Ionic liquid extraction systems was prepared by taking 
2.5 ml of 4 M K3PO4 salt with 0.1 ml 40~80% (w/v: weight/volume) ionic liquid [bmim]Cl. 
The other was consisted of 2.5 ml of 6 M K2CO3 salt with 0.1 ml 30~80% (w/v) ionic 
liquid [bmim]Cl. In each set of extraction systems, 0.1 ml of the target solution was 
added and was shaken for 10 min. Then, the ionic liquid phase was collected. No 
carrier added 195(m)Hg and 197(m)Hg radionuclides were extracted into the ionic liquid 
phase leaving gold residue in the salt rich phase. This single step offers excellent 
separation between carrier free Hg and gold target. Minimal volume (~0.1 ml) 
([bmim]Cl) was in the final product with around 95~97% of n.c.a. 195(m)Hg and 197(m)Hg. 
However, lacking of Hg back extraction method from ionic liquid phase as the fatal 
drawback restrict the applications of this method for radiopharmaceutical studies. 
 
Further investigations of TEVA resin were performed by the application. First of the 
shortcomings are the forms of extract salt. The eluted mercury(II) nitrate is more 
difficult to achieve the reaction with ligands in comparison to experiment with LN resin’s 
yielding mercury(II)chloride. Additionally, the process is unsatisfying due to a weaker 
separation factors. Lastly, the evaporation of excess HNO3 might lead to a large activity 
loss and time waste in contrast to the HCl evaporation in [197(m)Hg]HgCl2. Given that, 
another UTEVA® resin (Uranium und TEtraValents Actinides), which is mainly used for 
the separation of Uranium and tetravalent actinides like Np, Th and Pu, was not worth 
doing because of their similar drawbacks. Accordingly, this possibility was not pursued 
further. 
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Figure 3.7: Dipentyl pentylphosphate (DP[PP]) or Diamyl amylphosphate (DAAP). The UTEVA® resin is 
composed of DP[PP] also called DAAP “impregnated” onto an inert support. 
 
The method based on LN resin, its active component is the well-known HDEHP (see 
figure 3.8). It was found to be highly satisfactory because of the high radiochemical 
purity of the produced 197(m)Hg (higher separation factor), the high chemical yield with 
low product loss which can be determined with good accuracy. Advantages are also the 
simple procedure with better handling of automation and the short time required. But 
there are still drawbacks: 
Firstly, it is still lacking of alternative methods to remove the 6 M HCl instead of 
evaporation. To minimize the volatilization of [197(m)Hg]HgCl2, we left behind a small 
volume of residual solutions (less than 10 µl) after evaporation, because the critical 
activity loss occurs when the evaporate flask is completely dry. But the remaining HCl 
leads to a pH adjusting problem when the reaction condition should be neutral which 
will cause a larger volume of buffer added and irrelevant salt. 
It can still be seen that activity loss and time waste were the main problems in 
evaporation. Therefore, the study of a new approach to get rid of evaporation after 
separation is still ongoing.  
Secondly, the extraction with chloroform for the removal of HDEHP traces might 
sometimes cause activity loss. Fortunately, this is negligible compared with the 
evaporation of HCl.  
Thirdly, although gold recycle is not the main concerns of our studies, efficient 
approaches for multiple reuse have great importance for the process economy. There 
are large numbers of method for recycle use of gold, here list three of the common 
approaches: 
 
 (i) H+[AuCl4]- + (heat >254°C) → HCl + AuCl3  
   AuCl3 → AuCl + Cl2 (heat >160°C)  
   3AuCl → AuCl3 + 2Au (heat >420°C)  
   Keep heating AuCl3 to produce more gold medal 
 
(ii) H+[AuCl4]- + (heat >254°C) → HCl + AuCl3 
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     AuCl3 + 3 NaOH → Au(OH)3↓ + 3 NaCl 
4 Au(OH)3 + (heat >254°C) →4 Au + 6H2O + 3 O2 
 
(iii) 2 H+[AuCl4]- + 7 Na2SO3 → 2 Au+3 Na2SO4 + 8 NaCl + 4 SO2 + H2O 
 
(iv) ascorbic acid is also possible Au3+ reduction. 
 
Besides, the reduction of gold ion (Au3+) could also be performed by electrolysis for the 
recycling. In the frame of this work the real recycling was not investigated. 
 
 
 
 
Figure: 3.8 Eluted Gold traces before recycling. 
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Table 3.4: Alternative Hg/Au separation methods comparison.  
 Efficiency Processing 
time 
Hg 
purity Volume 
Solvent 
Hg Drawbacks Automatization 
Proven 
methods 
Distillation metal [92-
94] 
High (thin 
Au foils) 
Low (thick 
Au foils) 
>1h high 
medium or 
high 
conc. 
oxid. acid 
high 
temperature, 
thick Au foils 
usable? 
difficult  
HgCl2 sublimation[95] ? <2h ? variable variable 
HAuCl4 
sublimable difficult ✔ 
Liquid liquid extraction 
isoamylacetate[36] medium >3h medium precipitation / 
Long Processing 
time with 
multistep 
Insoluble 
low efficiency 
difficult  
Liquid liquid extraction 
MIBK [16, 44, 96] medium 2~3h medium low 2 M HCl low efficiency difficult ✔ 
Liquid liquid extraction 
Ionic liquid[97] high 2~3h high low 
Ionic 
liquid 
back extraction 
difficult difficult ✔ 
Liquid solid extraction 
TEVA resin[98] high ≈2h medium medium 
10 M 
HNO3 
evaporation of 
HNO3 simple 
✔ 
Liquid solid extraction 
LN resin high ≈2h high low 6 M HCl 
evaporation of 
HCl simple ✔ 
Variable 
Separation method 
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3.3 Development and evaluation of 197(m)Hg labeling units 
 
3.3.1 General remarks to n.c.a.197(m)Hg labeling 
Before labeling, series of tests should be done to discuss the basic properties of 
[197(m)Hg]HgCl2, HgCl+, Hg2+ and [HgCl4]2-. 
 
1.  0.1 M~0.2 M HCl is necessary used to redissolve [197(m)Hg]HgCl2, because Hg2+ 
needs comparable high ion concentration to remain in solution. However, for the most 
of labeling procedures, Hg2+ needs a comparable neutral environment to form R-Hg-R 
compounds. A higher concentration HCl was once assessed for labeling studies either 
(or HCl was not evaporated completely), which made it necessary to add more buffer 
during labeling procedure and lead to a higher volume of labeling products. Moreover, it 
caused higher concentration of salt and water left in the mixture, which might lead to 
problem separating the product for further studies. 
 
2.  Reaction temperature >50 °C would increase the risk for [197(m)Hg]HgCl2 sublimation 
from the reaction solutions, which may cause the loss of activity and dispersal of Hg 
compounds. Moreover, unlike other radiometals, mercury organometallics have strong 
tendency of volatility. To achieve the best radiolabeling efficiency, the temperature 
should be kept as low as possible. Room temperature is normally the best for labeling. 
If necessary, after incubating at high temperature, the reaction mixture (generally in 
organic solvent) needs to be cooled down on ice bath or solid CO2. 
 
3.  For the detection of Hg2+ in reaction solutions, Radio-TLC studies of [197(m)Hg]HgCl2 
should be performed in different pH solutions. Aqueous solution of [197(m)Hg]HgCl2 for 
labeling was kept in different pH conditions (pH 1, pH 3, pH 6, pH 7 and pH 8) by 
buffering with 0.2 M MES buffer solution and adjusting pH with 0.2 M NaOH solution 
and determined using Tritest-pH indicator paper (Merck). It is shown in Figure 3.9, 
[197(m)Hg]HgCl2 in different pH were monitored via radio-TLC at room temperature. 
Owing to complicate TLC factures of mercury products, unlabeled [197(m)Hg]HgCl2 and 
the labeling units should be both determined with multiple TLC plates, by using iTLC-
Silica Gel plates with a solution of 100/1 (v/v) CH3CN and acetic acid as the mobile 
phase (Method 1); and using RP-18 modified TLC plates with a solution of 
90/10/0.1(v/v/v) CH3CN, H2O and TFA acid as the mobile phase (Method 2). On SG 
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 <    < Oxalate 
Figure 3.10: The competing agents Cysteine, DMSA and NS3 (10 mM stock solution, with the -HS 
concentration ratio =1:2:3) 
 
 5.  In our early studies, considering the impurities in [197(m)Hg]HgCl2, we met difficulties 
in labeling procedure. Sometimes when labeling conditions were at pH>6, 
[197(m)Hg]HgCl2 and/or 197(m)Hg]Hg(OH)2 precipitates together with gold metal 
(colloid/nanoparticle) and formed hydroxide species. The problem was solved until we 
developed a new extraction method based on LN resin. But still, when pH>6, 
[197(m)Hg]HgCl2 tends to form Hg(OH)2 which eventually condensates to HgO and tends 
to participate. Thus, in the procedure of labeling, ligands should be added into reaction 
mixture immediately after buffer, not only to keep a neutral environment but also to 
avoid the decomposition of ligands. 
 
6.  Although the activity level of [197(m)Hg]HgCl2 is high enough for labeling studies and 
animal SPECT imaging studies, there are still several limitations. In opposite to 
application of the common radionuclides used for SPECT, the labeling procedure of 
[197(m)Hg]HgCl2 is more complicated. In order to stable radiomercury compounds, 
multistep reactions are necessary. Accordingly, the absolute yields are low and SPECT 
imaging might be not possible anymore. Besides, the limited activity leads to the 
exclusion of extensive HPLC purification (semi preparative) presently. 
 
 
3.3.2 Hg-N compounds: Radiolabeling and stability studies of N-bearing 
macrocyclic ligands with 197(m)Hg 
Initially, some of potential chelators should be evaluated if they are suitable for 197(m)Hg 
labeling. The main substances for chelating should be commercial available and easy 
for re-design based on it. Historically, it is known that the Hg2+ ions tend to form bonds 
with nitrogen atoms. Cyclic (macrocyclic) and acyclic tetradentate chelators (N4, N2O2 
and N2S2) were favored in order to stabilize Hg ions and as the methods of detection 
and deactivation of the highly toxic Hg2+. Therefore, it was easy to find studies of 
mercury complexes with nitrogen-containing chelator, among some which might be 
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suitable for [197(m)Hg]HgCl2 labeling.  
 
3.3.2.1 Radiolabeling study of [197(m)Hg]Hg-bispidine 
Bispidine (3,7-diazabicyclo[3.3.1]nonane) derivatives are one of obvious interest in 
particular. bispidine and its derivatives are known to form a chelate complexes with the 
64Cu with high stability and kinetic inertness [100, 101]. A chelate complex with mercury 
ion was reported either [102]. From the copper chelation, we speculate a similar 
structure of a [197(m)Hg]Hg-bispidine results in the formation of approximately symmetric 
N-Hg-N bonds. Structure of bispidine and assumed chelating structures is seen in 
Figure 3.13 a.  
 
Bispidine as chelator was radiolabeled using [197(m)Hg]HgCl2 in 0.2 M MES buffer (0.1 M 
NaOH) in pH 6.0 solution at 50 °C. The pH value of the resulting solution was always 
determined using Tritest-pH indicator paper (Merck). Within 60 mins, the extent (RCY) 
of 197(m)Hg-complex was determined by radio-TLC with Silica Gel plate mobile phase 
Method 1 (described in 3.3.1) and RP-18 plate mobile phase Method 2 (described in 
3.3.1). On SG plate: [197(m)Hg]Hg-bispidine moves with the solvent front while 
[197(m)Hg]HgCl2 contaminate remains at the starting pot; on RP-18 plate: Rf~0.65 for 
[197(m)Hg]Hg-bispidine, while [197(m)Hg]HgCl2 contaminate remained at the starting spot. 
These studies showed a 50% radiolabeling after 60 min (Figure 3.11 b red). Longer 
labeling time and increasing the temperature up to 70 °C did not affect the radio-
complex.  
Stability (challenge) study is necessary to in order to ensure the proposed 197(m)Hg 
chelating units are stable against the large presence of free thiols in vivo. 
Consequently, cysteine soaked TLC plates were employed to determine the relative 
stability against competing thiols. Same as well, cysteine soaked iTLC-Silica Gel 
mobile phase: Method 1 (described in 3.3.1) and cysteine soaked RP-18 mobile phase: 
Method 2 (described in 3.3.1) were carried out either. The result (Figure 3.11 b blue) 
shows that both of TLC plates remained at the origin which indicated that [197(m)Hg]Hg-
bispidine complex shows very weak stability against cysteine. 
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sulfur chelators generally (compare 3.3.3). Moreover, relatively little is known about 
their thermodynamic stability and the stability against thiols. According to the results, 
the rapid decomposition of Hg-N bond in solution and very weak stability against thiols 
let us conclude: Hg-N based chelates will not be a good choice for table Hg-complex. 
 
 
3.3.3 Hg-S compounds: Radiolabeling and characterization of mercury tetra-
thiolate compounds ([197(m)Hg]2) 
Mercury has a great affinity for sulfur in general which indicates that Hg complexes or 
even Hg covalent Hg-S compounds are a choice for stable 197(m)Hg labeling. A variety of 
sulfur based ligands for Hg selective chelating have been synthesized and evaluated 
so far. The development of linear bond S-Hg-S complexes is one of the most interest 
possibilities to numerous novel ligands. For example, commercial agents DMSA 
(dimercaptosuccinic acid) and NBMI (bis(2-mercaptoethyl) isophthalamide) were used 
for detoxification of mercury [104]. While, many of Hg-S bond complexes have very 
weak solubility and easy to precipitate in solution. Further studies are needed to 
examine the stability and solubility. 
 
3.3.3.1 Radiolabeling study to synthesis [197(m)Hg]2 
A tetra-thiolate ligands (1) (N,N'-(azanediylbis(propane-3,1-diyl))bis(5-(morpholine-4-
carbonyl)-2-thioxo-1,3-dithiole-4-carboxamide)) was synthesized 1. The structure of 1 
and probable chemical structure of synthesized [197(m)Hg]2 is shown in Figure 3.13 a. 1 
could provide -SH to react with [197(m)Hg]HgCl2. The bond formation of [197(m)Hg]2 
chelate complexes should be mono or double linear binding, in which two thiolate S 
atoms bind with a Hg center (S-Hg-S).  
 
A prior chemical procedure was performed to release four thiols (pH>9) from the ligand. 
To reach this, 1 was dissolved in acetonitrile as stock solution (1mg/ml). 50 µl CF2 
solution together with aliquots of 0.2 M MES buffer (pH 6.0~6.2) were added into 200 µl 
pH 9.0 ammonium acetate buffer (alternative 0.2 M NaOH solution) to short-term 
                                                 
 
1  The synthesis was performed by Christian Förster (Dissertation TUD/HZDR). Institute of 
Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf. 
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Thus, new labeling units need to be developed with high stability to ensure targeting 
the injected dose to the target organs. The conclusion of the in vivo studies is: 
[197(m)Hg]2 chelates will not be a good choice for table Hg-complex. 
 
 
3.3.4 Hg-S compounds: Synthesis, radiolabeling and stability studies of the 
bipodal dithiocarbamate ([197(m)Hg]4) 
Mercury could react with two or four cysteine molecules via sulfhydryl group. 
Analogously to [197(m)Hg]2, this inspired us to utilize the structure of four-coordination 
with mercury other than two-coordination. Novel chemosensors based on bipodal 
dithiocarbamate scaffold have been reported, which showed a remarkable selectivity 
on Hg2+ selection [105-107]. This bipodal thiocarbamate scaffold chelating unit, 
containing four donor atoms might shows stronger interactions with central Hg2+ ions 
than the simple two-coordination (linear S-Hg-S molecular geometry). In particular, by 
applying bidentate or polydentate dithiocarbamate ligands, the use of substances with 
this dithiocarbamate core for the detection of mercury could be demonstrated. We 
derivatized the bipodal dithiocarbamate scaffold with two pyridyl residues to provide 
sulfur atoms as donors and alter its binding affinity.  
 
The real structure of the Hg-bipodal thiocarbamate conjugate is still uncertain. From 
literatures, we can find two assumed different chelating patterns: “NS-Hg-SN” [105, 
106] and “SS-Hg-SS” [107].  
 
 
Figure 3.15: “Assumed” chemical structures of Hg-bipodal dithiocarbamates chelates (a):  Assumed 1 “NS-
Hg-SN” (b):  Assumed 2 “SS-Hg-SS”. 
 
The bipodal thiocarbamate scaffold compound (3) was synthesized as described in 
experimental section 5.4. The structure of 3 and the possible chemical structures of two 
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proposed binding modes of bipodal scaffold thiocarbamate with [197(m)Hg]Hg2+ are 
shown in Figure 3.16 a. The synthesized 3 was then radiolabeled with [197(m)Hg]HgCl2 
and the procedure was straightforward. 10 μl (1 mg/ml ethanol stock solution) 3 ligands 
was added into ca. 200 μl 0.2 M MES buffer (pH 6.0~6.2) together with aliquots volume 
of ethanol. To this solution, an aqueous solution of [197(m)Hg]HgCl2 (10 MBq, ca.10 μl) 
was added. Incubate the mixture at 50 °C for 60 min. Radio-TLC was used to confirm 
the [197(m)Hg]4 complexes with SG plate (Method 1: see 3.3.1) and RP-18 (Method 2: 
3.3.1) respectively (Figure 3.16 red). On SG: all activity remained at the starting point 
and useful not useful for analytical correlation. On RP-18: [197(m)Hg]4 moved to the 
middle of the mobile phase (Rf~0.6) whereas [197(m)Hg]HgCl2 remained at starting spot, 
which confirmed a ~70% radiochemical yield. The remaining counts under the line 
were found to be very low during radio-TLC study. The labeling ratio was measured on 
the activity counter and was calculated using the equation (total radioactivity - 
radioactivity left in vial) / total activity100%. The calculated yield was under 30% which 
indicated the precipitation of [197(m)Hg]4.  
Besides, stability studies need to be performed to test [197(m)Hg]4 in simulated in vivo 
conditions. Cysteine soaked SG (Method 1: see 3.3.1) and RP-18 (Method 2: see 
3.3.1) were developed for radio-TLC studies. As seen in Figure 3.16 blue, most of 
activity was found to stay at the starting pot in both plates. The stability study indicated 
that [197(m)Hg]4 chelates are not stable against the competing cysteine. 
 
 
                      3                                                                    [197(m)Hg]4 
 
Figure 3.16 a: Structure of 3 and assumed chelating structure of [197(m)Hg]4. 
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(Te-Hg-Te) together with a weak Nitrogen binding.  
For comparison purposes, the analogues compound 5 has been synthesized (Figure 
3.17a). 
 
3.3.5.1 Radiolabeling and stability study of [197(m)Hg]6 
The white crystalline solids 5 was synthesized 2. Figure (3.17 a) shows the structure of 
ligand 5 and the proposed structure of [197(m)Hg]6. 5 was radiolabeled using 
[197(m)Hg]HgCl2 with 0.2 M MES buffer (0.1 M NaOH) in pH 6.0 solution at 50 °C. The 
pH value of the resulting solutions was always determined using Tritest-pH indicator 
paper (Merck). Within 60 mins, the extent (RCY) of 197(m)Hg-complex was determined 
by radio-TLC (Figure 3.17 b) with Silica Gel (SG) (Method 1: see 3.3.1) and RP18 
(Method 2: see 3.3.1). On SG plate: [197(m)Hg]6 moved with solvent front (~50%) while 
[197(m)Hg]HgCl2 remained at starting point, which indicated the RCP of [197(m)Hg]6 is 
approximately 50%. On RP-18 plate: most of activity remained at the starting point 
which was impossible for the analysis of RCP. 
The labeling was carried out without any buffer in ethanol. [197(m)Hg]HgCl2 was 
evaporated to complete dryness, then labeling procedure was assessed. The utilization 
of ethanol did not affect the radio-complex which leaded to a low RCP of the [197(m)Hg]6 
complexes.  
It was also necessary to test the stability against competing thiols. Consequently, 
cysteine soaked TLC plates (SG and RP-18) were employed with the same mobile 
phase.  
As seen in Figure 3.17 b blue, very high activity remained at the starting point for both 
plates. Obviously Rf value changes is shown on SG plate with the transchelation 
happened. The result of TLC plates indicated that [197(m)Hg]6 complexes show 
instability against cysteine. 
 
 
                                                 
 
2 The synthesis was performed by Mrs. Bianca Kreisl, Institute of Radiopharmaceutical Cancer Research, 
Helmholtz-Zentrum Dresden-Rossendorf. 
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3.3.6 Hg-organometallics: Radiosynthesis of [197(m)Hg]phenyl-HgCl and 
([197(m)Hg]10) and [197(m)Hg]diphenyl-Hg ([197(m)Hg]11) via electrophilic aromatic 
substitution of tributyl(phenyl)stannane precursor 
 
Mercury is unique among metals in its capability to form covalent Hg-C bonds and has 
its own organic chemistry because the existence of large numbers of Hg-
organometallic compounds. Other than previously described Hg-S based chelating 
units, 197(m)Hg-organometallics might be an alternative approach. As shown in Table 3.5, 
the Hg-C bond of diphenylmercury (derivatives) show higher bond-dissociation 
energies in comparison to Hg-S complex. To classify the strength of the Hg-C bond-
dissociation energy: a typical C-C bond has a strength of about 350 kJ/mol, while the 
C6H5-HgC6H5 is 285kJ/mol. Compared with alkylmercuries, the aromatic systems 
stabilize the structure of diphenylmercuries, which might cause a higher bond-
dissociation energy. 
 
 
Bond-dissociation energies of several Hg-R bonds (kJ/mol) 
Bond kJ/mol Bond kJ/mol 
Hg-Hg 17.2 Hg-F 130 
Hg-H 39.8 Hg-Cl 100 
Hg-K 8.24 Hg-Br 72.8 
Hg-Na >6.7 Hg-I 38 
Hg-S 213 C6H5-HgC6H5 285 
Hg-Se 167 C2H5-HgC6H5 182.8 
Hg-Te 142 CH3-HgCH3 240.6 
 
Table 3.5: Bond dissociation energies of several Hg-R bonds 
 
Accordingly, 197(m)Hg labeled organometallics especially diphenylmercury derivatives 
are of great interest in radiopharmaceutical studies. There are still lack of further 
stability and solubility studies. Thus, [197(m)Hg]phenyl-HgCl and 
[197(m)Hg]diphenylmercury derivatives should be radiosynthesized via electrophilic 
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3.3.6.3 Stability of [197(m)Hg]10 and [197(m)Hg]11 in the reaction mixtures 
For potential radiopharmaceutical application, 197(m)Hg labeled compounds must be 
kinetically inert and high thermodynamically stable even under physiological 
environment. Thus, the stability of [197(m)Hg]10 and [197(m)Hg]11 were examined in their 
reaction mixtures. The resulting reaction mixtures of [197(m)Hg]10 and [197(m)Hg]11 were 
kept at 37 °C for a period of time (up to 48 h) without any addition. At 1 h, 24 h and 48 
h, sample of the mixture was taken and analyzed by radio-TLC (RP-18 with mobile 
phase Method 2). As shown in Figure 3.21, both [197(m)Hg]10 and [197(m)Hg]11 showed 
high stability with >90% radiochemical purity up to 48 h ([197(m)Hg]10 approximately 
90% at 48 h). 
Figure 3.21: Stability study of [197(m)Hg]10 and [197(m)Hg]11 reaction mixtures within 48 h determined by 
Radio-TLC (RP-18). RP18 plate mobile phase: CH3CN/H2O/TFA acid 90/10/0.1 (v/v/v). 
 
Summary to 3.3.6: 
To conclude, applying organotin compounds enable working condition at room 
temperature (if necessary) and short reaction time. Additionally, only minor amounts of 
organotin precursor (9) are necessary in the range of ~10 μg. Radioactive 
phenylmercury chloride ([197(m)Hg]11) was obtained at pH1 and diphenylmercury 
([197(m)Hg]11) at pH6. Considering the poor solubility of simply diphenylmercury 
compounds, the resulting mixtures were kept in aqueous organic solvents (50% DMSO 
or 90% ethanol). But over half of radioactivity was still sticking on Eppendorf vial. In 
order to reduce the interaction of 197(m)Hg compounds with surfaces, many efforts have 
been made. The reaction vessel was incubated with small quantities of blocking agents 
individually before labeling process (amino-benzoic-acid, toluene-4-sulfonic-acid, 
vanillin, ZnCl2, and S-benzyl-L cysteine). Same efforts have been made after the 
reaction finished. 
However, the labeling yield didn’t show any improvement. It didn’t work either when 
changed to low DNA or protein binding Eppendorf vial as the reaction vessel. By a 
comparable study, one feasible approach was the utilization of glass bottle as the 
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reaction vessel instead of Eppendorf vial which showed less adsorption at the vessel 
walls and corresponding higher activity in solution. 
 
 
3.3.7 Hg-organometallics: Radiosynthesis of [197(m)Hg]13 and [197(m)Hg]14 via 
electrophilic aromatic substitution with imidazole derivative (12) precursor 
 
In the course of the following work, the water solubility of the tributyl(phenyl)stannane 
precursors should be improved (e.g. 9). Suitable modifications of benzoyl-derivatives 
can be utilized as the efficient platforms to form versatile 197(m)Hg labeling units for 
various biomedical applications. These trialkyltin-precursors could be prepared (Figure 
3.22) from bromine derivatives by palladium catalyzed deiodostannylation utilizing 
hexamethylditin or hexabutylditin as the stannane source [111-113]. An imidazole 
derivative (structure is seen in Figure 3.22 a) (N-(2-(2-methyl-5-nitro-1H-imidazol-1-yl) 
ethyl)-4-(tributylstannyl)benzamide) (12) of interested was synthesized 4. 
 
  
Figure 3.22: Synthesis scheme of trialkyltin-precursors with bromine derivatives 
 
3.3.7.1 Radiosynthesis and stability study of [197(m)Hg]13 
The radiolabeling procedure was described in Method A (see 5.5.1) and 197(m)Hg 
labeling was determined by radio-TLC (Figure 3.23 b red). On SG (Method 1: see 
3.3.1): the [197(m)Hg]13 derivative moved with the solvent front. On RP-18 (Method 2: 
see 3.3.1): Rf~0.8 was found for the [197(m)Hg]13 derivative. These studies showed 
labeling yields of >99%. 
Stability studies were conducted with the same procedure for unmodified [197(m)Hg]10. 
NS3 soaked RP-18 was carried out (Figure 3.23 b blue), most of activity nearly 
                                                 
 
4 The synthesis was performed by Mrs. Bianca Kreisl, Institute of Radiopharmaceutical Cancer Research, 
Helmholtz-Zentrum Dresden-Rossendorf. 
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for both compounds (Figure 3.25). Therefore, [197(m)Hg]13 and [197(m)Hg]14 both show 
high stability with >90% radiochemical purity up to 48 h. 
 
Figure 3.25: Stability of 197(m)Hg labeled imidazole derivatives ([197(m)Hg]13 and [197(m)Hg]14) reaction 
mixtures within 48 h determined by Radio-TLC. RP18 plate mobile phase: CH3CN/H2O/TFA acid 90/10/0.1 
(v/v/v) 
 
3.3.7.4 Effect of pH on the reaction of imidazole derivatives with 197(m)Hg 
Considering the high radiolabeling yield of [197(m)Hg]13 and [197(m)Hg]14, this imidazole 
precursor (12) was used to investigate the effect of pH to the electrophilic aromatic 
substitution of 197(m)Hg. 10 μl 12 precursor (1 mg/ml stock solution) was labeled with 
197(m)Hg at pH 1 as Method A (see 5.5.1), radio-HPLC was used to confirm the identity 
of the products after 60 min (retention time of [197(m)Hg]13: 14.8 min). Then, 200 μl 0.2 
M MES together with 50 μl 0.2 M NaOH were added. 50 μl of the sample were taken 
instantly for radio-HPLC study (0 min, pH 6). As seen in Figure 3.26, a new higher peak 
was found at 21.4 min, which indicated [197(m)Hg]13 reacted with 12 and formed 
[197(m)Hg]14 (retention time: 21.4 min) immediately at pH6. [197(m)Hg]13 (retention time: 
14.8 min) and [197(m)Hg]14 (retention time: 21.4 min) show obvious variations in 
retentions of HPLC. After another 60 min incubation at pH6 at room temperature, the 
resulting solution was determined via radio-HPLC again. At this time, only one peak 
remained at 21.4 min, which indicated that the rest of [197(m)Hg]13 reacted with 12 and 
formed [197(m)Hg]14 (retention time: 21.4 min). All HPLC runs are performed under the 
same conditions with the same HPLC-equipment. Column: Zorbax C18 column with 
inner diameter of 8 mm. Mobile phase: H2O + 0.1% TFA (A) and CH3CN + 0.1% TFA 
(B). Flow rate: 3 mL/min. HPLC gradient of B phase: in 0~30 min from 10% to 60%, in 
30~40 min from 60% to 95%, 40~41 min from 95% to 10%. 
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3.3.7.6 Attempts for determination of effective molar activity for the radioactive 
arylmercury derivatives 
The specific activity (As) or molar activity (Am) of radionuclides is particularly relevant 
when it comes to select them for production for theranostics pharmaceuticals, among 
several other biomedical applications. The calculation of maximum theoretical specific 
activity (As) or molar activity (Am) is shown below.  
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λ=decay constant; N=number of atoms; NA=Avogadro's constant; n=amount of substance (mole); A= 
activity. 
 
The maximum theoretical molar activity of 197Hg was calculated with this equation to be 
(Am,max=0.693/23076061023=1.8011018 Bq/mol=1801 GBq/µmol). Under a certain 
condition of n.c.a. [197(m)Hg]HgCl2, the “effective specific or molar activity” addresses the 
radio-chemically ‘active’ fraction of 197(m)Hg radiolabeled compounds. A high labeling 
efficiency with high effective As (Am) of radiolabeled compounds are usually more 
suitable for clinical applications. Determination of effective Am was not only necessary 
for quantitative analysis of preparative ligand quantities for [197(m)Hg]phenyl-HgCl and 
[197(m)Hg]diphenyl-Hg derivatives, but also in comparison with the modified imidazole 
derivative (12) and unmodified tributylphenyltin ligands (9) for labeling. 
 
The method for the determination of As is based on the prerequisite of a quantitative 
stoichiometric reaction of [197(m)Hg]HgCl2 with the trialkyltin precursors (9 and 12). Due 
to radioactive decay, the measurement time for the molar activity was set at the end of 
synthesis.  
Briefly, decreasing amount of 9 (10 μg, 5 μg, 1 μg... 110-3 μg, 510-4 μg) or 12 (10 μg, 
5 μg, 1 μg... 510-4 μg, 110-4 μg, 510-5 μg) were added to aliquots of [197(m)Hg]HgCl2 
(approximately 5 MBq measured in calibrator individually after labeling process). The 
pH value was determined using Tritest-pH indicator paper (Merck). Subsequently, 
labeling studies were performed twice in different conditions of incubation (25 °C for 3 h 
or 50 °C for 1h). The radiochemical purity of 197(m)Hg labeling was assessed via radio-
TLC. The calculated conversion rates closer to 50% were selected from dots with same 
labeling conditions as the one for the determination of effective Am value of this labeling 
reaction.  
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determination of Am is extremely difficult, all 197mHg was identified as ground state 197Hg 
to simplify the calculation. Although not precisely enough, it is still valuable for a 
qualitative study. 
 
 
3.3.8 Hg-organometallics: alternative approaches for the radiosynthesis of 
arylmercury with tetraorganoborate precursors  
As reported [114-117], tetraorganoborate derivatives could also be used potentially as 
the precursor for the radiosynthesis of [197(m)Hg]diphenyl-Hg derivatives. The 
mechanism is electrophilic aromatic substitution which is the same as trialkyltin 
precursors, but with triphenylborane as leaving group instead of tributylstanne. Herein, 
alternative approaches were performed for the radiosynthesis of arylmercury with tetra-
organoborate precursors. 
 
3.3.8.1 The alternative radiosynthesis of [197(m)Hg]diphenyl-Hg ([197(m)Hg]11) 
Sodium tetraphenylborate (15) consists of a central boron atom with four phenyl 
groups. The alternative radiosynthesis scheme of [197(m)Hg]11 with 15 is shown in 
Figure 3.29 a, the labeling procedure is similar with described Method B (see 5.5.2). 
For the radiosynthesis of [197(m)Hg]11 with 15, the extent (RCY) of 197(m)Hg-complexes 
was analyzed by radio-TLC (Figure 3.29 b red), on SG plate (Method 1: see 3.3.1): 
[197(m)Hg]11 moved with the solvent front; on RP-18 plate (Method 2: see 3.3.1): 
Rf~0.70 for [197(m)Hg]11, which showed a similar Rf value as labeled with 
tributylphenyltin precursor (9). These studies showed labeling yields of >90%. 
For the determination of the stability in the reaction mixture (0~5% DMSO, pH 6) the 
substance was kept for 12 h at room temperature. It was assessed via radio-TLC again 
with RP-18 plate (Method 2: see 3.3.1). As seen in Figure 3.29 b blue, ~60% of activity 
still remained at Rf~0.70 for [197(m)Hg]11, while ~40% of 197(m)Hg(II) sticks at starting pot. 
It indicates that [197(m)Hg]11 shows weak stability when labeling with 15 in the reaction 
mixture. 
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[118] They are electron-rich nucleophiles, and can form stable metal complexes with 
many transition metals due to its strong σ-donating property (π-donating and σ-
accepting character of the nitrogen atoms) [119]. Major applications of NHCs extend 
across a wide range, which was classified into the three categories. In the first two, 
NHCs were coordinated to metals and p-block elements and the third section details 
the applications of NHCs as organo-catalysts [120]. Almost every transition metal 
NHCs complexes have been reported [119, 121, 122], particularly in the area of 
catalysis.  
 
The first NHC mercury complex was reported in 1968, made by reaction of an 
imidazolium salt with a basic mercury source, mercury(II) acetate [123]. It shows great 
potentiality for 197(m)Hg labeling, because one of the promising properties was metals 
forming carbene-complexes that are usually resistant to decomposition [119, 121, 122]. 
Although mercury complexes were one of the first NHC-metal complexes synthesized, 
mercury complexes are the least studied among all literatures, because Hg(II)-carbene 
complexes usually been used as considerably efficient carbene transfer agents for 
synthesis of various types of transition metal-carbene complexes. Due to the high 
purity of the [197(m)Hg]Hg2+ solution in the labeling study, transchelation reaction should 
be of no significance. 
 
 
 
Figure 3.31: Hg(II)-N-heterocyclic carbene complexes [124]. 
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3.3.9.1 Radiosynthesis of [197(m)Hg]19 
A novel N-Heterocyclic carbene (18) (2,6-bis((3-methyl-2,3-dihydro-1H-imidazol-1-
yl)methyl)pyridine) was synthesized 5 and labeled with 197(m)Hg for characterization.  
 
The substance was intended to be the precursor for the labeling with [197(m)Hg]HgCl2. 
As the reaction has to be performed in organic solvent, a new TLC system had to be 
implemented for unreacted [197(m)Hg]HgCl2. 20 μl [197(m)Hg]HgCl2 (ca. 20 MBq) were 
added to a glass flask. The HCl solvent was removed in an evaporator. Then dried 
[197(m)Hg]HgCl2 salt was redissolved in 100 μl acetonitrile and applied for radio-TLC 
study.  On SG (Method 1: see 3.3.1): [197(m)Hg]HgCl2 in ACN solution moved with the 
solvent front; On RP-18 plate (Method 2: see 3.3.1): Most of activity continues spread 
between Rf 0~0.5. 
 
The labeling procedure was quite straightforward, 100 μl 18 (1 mg/ml acetonitrile stock 
solution) was added to this solution ([197(m)Hg]HgCl2 redissolved in acetonitrile). The 
reaction was performed at 70 °C for 24 h. The extent (RCY) of labeling was determined 
by radio-TLC after the mixture was cooled down in ice bath. [197(m)Hg]19 complexes 
remained at starting point on both plates (SG and RP-18), which showed no additional 
peak to confirm the substance in comparison to [197(m)Hg]HgCl2.  
In order to compare with the former approach and as challenge experiment, the Hg-C 
bond incorporating [197(m)Hg]19 complex was then examined with trialkyltin precursor 
(12) as the competing agent. 10 μl 12 (1mg/ml stock solution) imidazole organotin 
precursor was added to the reaction mixture and incubated at 50 °C for 1 h. The extent 
(RCY) of [197(m)Hg]19 carbene transreaction was monitored via radio-TLC (Figure 3.32 
b). On SG (Method 1: see 3.3.1): part of activity moved with the solvent front, which 
leaded to ~40% [197(m)Hg]19 remained at starting point; On RP-18 plate (Method 2: see 
3.3.1): Rf changed to ~0.80 for 197(m)Hg-complex which indicated that the transreaction 
between [197(m)Hg]19 and organotin precursor happened. Obviously, the resulting 
mixture containing both, [197(m)Hg]14 and [197(m)Hg]19. Then, the reaction mixture was 
incubated in 50 °C for another 2 h. On SG (Method 1: see 3.3.1): major part of activity 
moved with the solvent front; On RP-18 plate (Method 2: see 3.3.1): new 197(m)Hg 
labeled compound was formed (Rf~0.65), which indicate that [197(m)Hg]14 was probably 
generated after 3 hours incubation in [197(m)Hg]19 solution. 
                                                 
 
5 The synthesis was performed by Mrs. Bianca Kreisl, Institute of Radiopharmaceutical Cancer Research, 
Helmholtz-Zentrum Dresden-Rossendorf. 
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3.3.9.2 Synthesis of non-radioactive reference compound [natHg]19 
The non-radioactive [natHg]19 has been synthesized 6 as a reference compound for the 
corresponding radiomercury compound ([197(m)Hg]19). Initially, there was literature 
reported [natHg]19 was synthesized as reported by literature [125]. Reacting mercury 
chloride with N-heterocyclic carbene and the product was expected to precipitate as 
yellow powder. However, several attempts have been carried out but failed to synthesis 
[natHg]19 using mercury chloride determined via 1H-NMR. Fortunately, the Non-
radioactive [natHg]19 could be synthesized by reaction of N-heterocyclic carbene with 
mercury(II) acetate as most of the literatures reported [124, 126, 127]. Briefly, 11.47 mg 
18 was dissolved in 50 ml ACN. To this solution, 20 mg mercury(II) acetate were added 
(molar ratio=1:1). The mixture was stirred at 90 °C for 48 h. The yellow precipitation 
was collected and evaporated. A stability study was not performed owing to the weak 
stability of non-radioactive Hg-NHC against the competing thiols determined by 1H-
NMR (Supplemental Figure 2). 
 
To conclude, the labeling process of [197(m)Hg]19 was performed under relatively harsh 
conditions and the labeling yield was not able to be confirmed. Moreover, [197(m)Hg]19 
have a strong tendency to reacted with trialkyltin precursors (12), which indicated that 
[197(m)Hg]19 is not suitable as an alternative approach for the preparation of 197(m)Hg 
organometallics.  
 
 
3.3.10 Summary 
Since mercury shows strong ability on chelating with thiols containing compounds, a 
chelator based on the detoxification agent NBMI has already been synthesized 7 and 
radiolabeled in advance with 197(m)Hg by before our investigation started. However, the 
                                                 
 
6  [natHg]19 was synthesized by Thomas Wünsche (Master student of TUD/HZDR). Institute of 
Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf. 
7 NBMI based chelator (STC) was synthesized by Tom Peters (Master Dissertation 2014 TUD/HZDR). 
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stability of the 197(m)Hg labeled complexes was weak against competing thiols and 
therefore not suitable for application. 
 
 
 
Figure 3.33: Structure of NBMI and NBMI based 197(m)Hg-complexes (Tom Peters Master Dissertation 
2014) 
 
In this work, different types of sulfur rich ligands/chelators were radiolabeled with 
197(m)Hg based on chemosensors or chelators used for capturing Hg2+.  The evaluation 
studies of these Hg-S bond compounds showed critical results (weak stability and/or 
poor solubility). The reason is probably because of the unique properties of 
chemosensors: the minimum requirements for optimum sensors are efficient and 
selective trace mercury(II) ions capturing from aqueous solution, regardless of the 
states of chelating complex. In such a case, the chelating compound needs only “weak” 
stability. Strategies focusing on improvement of sensitivity and selectivity is the most 
important. Because in the removal and determination of Hg(II) ions, foreign ions might 
have strong interference. Certain but very low concentration of Hg2+ might also below 
the detection limit. 
In contrast, [197(m)Hg]HgCl2 for labeling has a high purity. Due to its n.c.a. states, 
[197(m)Hg]Hg2+ ions are present in a very low concentration. For development of Hg-
chelating/binding units, greatest emphasis has to be focused on stability and kinetics   
inertness of the resulting 197(m)Hg labeled compounds. 197(m)Hg chelating unit may have 
strong interferences with excess of thiols in human serum and transchelation may 
occur before reaching the targeted sites. Furthermore, solubility is another rigid 
demand for the applications not only to provide better labeling efficiency, but also for 
application purposes where it is bound to targeting vectors. Besides, 197(m)Hg labeled 
complexes should be mandatory non-toxic for injection.   
 
Another approach is based on Hg-organometallics, among them, strong aromatic Hg-C 
bond arylmercury compounds provide great potentials. Trialkyltin-precursors were used 
for the radiosynthesis of [197(m)Hg]phenyl-HgCl  and [197(m)Hg]diphenyl-Hg derivatives via 
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electrophilic aromatic substitution. To this reaction, [197(m)Hg]10 derivatives were 
obtained at pH 1 and [197(m)Hg]11 derivatives at pH 6. Diphenylmercury compounds 
show the highest stability against competing thiols in our study. Moreover, [197(m)Hg]14 
obtained from an imidazole derivative (12) was determined with high labeling efficiency, 
high stability and high effective As. The solubility of [197(m)Hg]14 is obviously improved 
compared to [197(m)Hg]11. Therefore, for the future investigation to the radiosynthesis of 
[197(m)Hg]11 based small molecules, the focus of the work has to be strictly 
concentrated to water soluble molecules. 
 
 
3.4 Asymmetric 197(m)Hg labeling units: radiosynthesis of dithiocarbamate 
arylmercury compounds 
Dithiocarbamates (dtc) are carbamates in which both oxygen atoms are replaced by 
sulfur atoms. They have been used as ligands for chelating (soft) metals [128]. The 
sulfur donors of dithiocarbamate have a greater propensity for mercury than thiols and 
show versatile coordination chemistry and material properties. Dithiocarbamates with 
simple amines are used for highly selective Hg2+ electrodes and for other heavy metals 
[129]. In addition, dithiocarbamate ionophores have been used to develop novel optical 
sensors for environmental Ag+ and Hg2+ analysis [130]. In a word, dithiocarbamates 
formed very stable chelates with Hg2+ ions as report and show a higher affinity for 
dithiocarbamate than thiol groups [131]. This fact prompted us to make use of it as the 
ligand for 197(m)Hg labeling. 
 
3.4.1 Synthesis of dithiocarbamates  
Dithiocarbamates are usually prepared by the nucleophilic addition of many primary 
and secondary amines to carbon disulfide (Figure 3.34). Since the free acids thus 
obtained are unstable, the reaction must be conducted in the presence of a base like 
sodium (potassium) hydroxide, to isolate the corresponding dithiocarbamate salts [132, 
133].  
 
 
Figure 3.34: Synthesis scheme of dithiocarbamates with primary and secondary amines 
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In the following, we synthesized a series of dithiocarbamate ligands for the 197(m)Hg 
labeling and stability studies. As summarized in table 3.7, the preparation of 
dithiocarbamate derivatives was performed according to reactions reported [134, 135], 
based on this one step reaction. These include salts of the double-deprotonated 
dithiocarbamato fatty acid, decane- and di-ethyl derivatives (See 5.4.1~5.4.5). 
 
 
No. Structure No. Structure 
20 
 
21 
 
22 
 
23 
 
24 
 
25 
 
(commercial available) 
 
Table 3.7: Lists of synthesized dithiocarbamates: fat acid-, decan- and diethyl- derivatives (See 
5.4.1~5.4.5). 
 
 
3.4.2 Radiosynthesis of symmetric 197(m)Hg labeled dithiocarbamates ([197(m)Hg]26) 
The symmetric 197(m)Hg labeled dithiocarbamates was first prepared to examine the 
possibility of stable approach with 22 as example (Figure 3.35 a). Briefly, 20 μl 22 
(1mg/ml stock solution) was dissolved into 100 μl 1 M MES buffer (pH 6.0~6.2). To this 
solution, 10 μl [197(m)Hg]HgCl2 (~10 MBq dissolved in 0.1 M HCl) were added slowly. 
The pH value was determined using Tritest-pH indicator paper (Merck). 
Dithiocarbamate ligands should be buffered before [197(m)Hg]HgCl2 added, because 
dithiocarbamate was not stable in acidic solution. The following decomposed CS2 could 
react with the 197(m)Hg labeled complex and precipitated as [197(m)Hg]HgS. For 
preparation of the chelate, the mixture was stirred (1000 rpm) at 25 °C for 3 h.  
Radiochemical purity was determined by radio-TLC after reaction (Figure 3.35 b red). 
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stability. The stability against thiols are still needs to be examined. 
 
 
3.4.3 The Radiosynthesis strategy of asymmetric dithiocarbamate arylmercury 
compounds  
Comparing with unstable phenyl197(m)HgCl derivatives, symmetric [197(m)Hg]11 
derivatives show high stability against thiols. However, the symmetric chelation pattern 
which could cause double targeted agents doesn’t always mean a higher affinity 
towards the targeting sites. It may also cause weaker pharmakinetics in human body 
on the contrary. Aryl-mercury based targeted molecules suffer on low solubility in 
aqueous environment, mono-substituted and symmetric di-substituted in particular. The 
[197(m)Hg]monophenyl-HgCl derivative was easily obtained and is able to conjugate with 
another chelating or specific targeted molecule. 
Accordingly, we tested to utilize the [197(m)Hg]monophenyl-HgCl as binding block for 
coupling to offer moieties to improve solubility and for targeting purpose, as well. This 
means, the asymmetric dithiocarbamate arylmercury derivatives were focused to 
facilitate multiple functionalization theoretically: one specific targeting molecule (Hg-C) 
plus one site for tuning of solubility and excretion behavior (Hg-S).   
 
The water stable non-radioactive asymmetric dithiocarbamate arylmercury compounds 
have emerged to an active area of research in chemistry in recent years with various 
reported studies, which are interesting from the viewpoint of their electrical conductivity, 
molecular magnetism, electrochemical properties, biological processes and 
optoelectronic properties [137-141]. The formation of dithiocarbamate arylmercury 
molecule showes linear coordination and high thermodynamic stability [142]. As 
reported, phenyl-mercury chloride [143, 144] and diphenylmercury [145] can both react 
with dithiocarbamate and form dithiocarbamate arylmercury compounds, which 
provides us the potential strategy for the radiosynthesis. 
 
 
 
Figure 3.36: Synthesis pathway to dithiocarbamate phenylmercury derivatives based on phenylmercury 
chloride or diphenylmercury [143-145]. 
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To achieve this, [197(m)Hg]monophenyl-HgCl derivatives should be synthesized first, with 
dithiocarbamates added in the last step (Method C: see 5.5.3). According to this 
labeling strategy (Figure 3.37), one of the potential risks is the ‘side’ reaction with 
[197(m)Hg]monophenyl-HgCl: [197(m)Hg]diphenyl-Hg derivatives would be obtained in the 
2nd step if the concentration of trialkyltin precursor is not appropriate. However, by 
limiting the quantity of trialkyltin precursors for [197(m)Hg]monophenyl-HgCl 
radiosynthesis might leads to a very low labeling efficiency. Thus,  an new approach 
was developed to decompose the excess of trialkyltin precursors left in 1st step in acidic 
environment.  
 
  
 
Figure 3.37: Radiosynthesis scheme of dithiocarbamate arylmercury 
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utlized to conduct the stability of [197(m)Hg]27 and to confirm whether transchelation 
happens. ~10 MBq [197(m)Hg]27 was incubated with an excess of 10 mM cysteine or 10 
mM DMSA separately at 37 °C. Samples were taken for radio-HPLC analysis at 
different time points after mixing (1 h, 24 h and 48 h). At 1 h (Figure 3.42 A), 
[197(m)Hg]27 remained its high composition at 9.3 min together with a very weak signal 
at 4.4 min. No significant variations of composition were observed in challenge 
experiments after 1 h of incubation at 37°C with cysteine, which indicated no 
transchelation happened between [197(m)Hg]27 and cysteine.  While time is expanding, 
the composition of [197(m)Hg]27 decreased in the solution containing excess of cysteine, 
nearly half of activity retained at 4.4 min and RCP of [197(m)Hg]27 reduced to ~50% at 
24 h. The significant RCP variations indicated that the risk of transchelation between 
[197(m)Hg]27 and cysteine is increasing with time. After 48 h, no intact [197(m)Hg]27 
(retained at 9.3 min) was found. 
 
Challenge experiment with DMSA exhibited major instability already after 1 h (Figure 
3.42 B). It indicated that asymmetric dithiocarbamate arylmercury derivative cannot 
with stand the strong competing thiols like DMSA. Moreover, the competing ability was 
growing with the increasing relative number of sulfhydryl group in competing 
substance’s molecule.  
 
   
Figure 3.42 A: Radio-chromatograms of [197(m)Hg]27 after challenge experiment with 10 mM cysteine for 1 
h, 24 h and 48 h at 37 °C; B: Radio-chromatograms of [197(m)Hg]27 after challenge experiment with 10mM 
DMSA for 1 h. All HPLC runs are performed under the same conditions with the same HPLC-equipment. 
Column: Zorbax C18 column with inner diameter of 8 mm. Mobile phase: ddH2O + 0.1% TFA (A) and 
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CH3CN + 0.1% TFA (B). HPLC gradient of B phase: in 0~20 min from 45% to 80%, in 20~25 min from 80% 
to 100%. Flow rate: 3 ml/min. 
 
Although composition was decreasing, asymmetric dithiocarbamate arylmercury 
derivative [197(m)Hg]27 still show relatively high stability against competing cysteine 
during a longer time period which is worth enough for further investigations (still 
existing after 24 h). Non-radioactive [natHg]27 was investigated after 1 h of incubation 
at 37°C with cysteine and showed a similar result. 
 
 
3.4.4.5 Preparation of [197(m)Hg]27 for animal experiments (removal of organic solvent). 
 
The injection of radio-tracers needs the thorough preparation of the solution. This 
companies’ residues of organic solvent, content of salt, chemical and radio chemical 
impurities. In this case, it was necessary to remove the solvent CH3CN and ethanol, 
previously. Two methods for the removing solvents have been applied for [197(m)Hg]27 
samples:  
 
1. Evaporating organic solvent with N2 or Argon (indicated by volume difference), and 
subsequently re-dissolving the sample with 5~10% ethanol. However, in the process of 
treating [197(m)Hg]27 samples, a great activity loss was measured. It indicated that 
desired labeling products showed strong tendency of volatilization. Thus, this method 
could not be used to receive required 197Hg labeled units for animal experiments. 
 
2. Diluting the eluted sample until the concentration of ethanol was lower than 10% 
(acetonitrile lower than 1%). After the dilution, the total volume of solution was limited 
within 0.5 ml, which is the maximum dose for one rat injection. This method could be 
used to receive required volume and relatively high activity for the animal experiments, 
but containing traces of CH3CN. 
 
By neutralizing the pH of the reaction mixture, the excess of salts is increasing in the 
fraction, fortunately in the form of sodium salts. Even though organic solvent was 
removed or diluted, sodium salts are still a component of the mixture, which is likely to 
be a hidden trouble for animal experiment. For future animal experiment HPLC-
separation will by necessary applying an appropriate injectable buffer solution. 
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Besides, [197(m)Hg]13 was conjugated with other dithiocarbamates as well.  [197(m)Hg]27 
and [197(m)Hg]28 performed a good solubility and the injected substance was excreted 
mainly via the renal system and intestine as shown by small-animal SPECT imaging 
studies. 
 
3.5 197(m)Hg labeling of specific targeting molecules 
After the successful development of stable 197(m)Hg binding units, such as diphenyl-
mercury and dithiocarbamate phenylmercury derivatives, these most promising 
chelating patterns were coupled with specific targeting molecules in order to investigate 
the in vivo behaviors of 197(m)Hg labeled moieties, such as small molecules, peptides, 
aptamers, monoclonal antibodies, etc. For the radiolabeling of large molecules, 197(m)Hg 
was pre-labeled with trialkyltin-benzoyl-NHS to form pre-chelates (a) first. The 197(m)Hg 
pre-labeled unit could be conjugated with polystyrene microparticles (b) or antibodies 
(c) like Cetuximab [146] (EGFR targeting, C225) via the active ester and then 
employed for SPECT imaging studies. Besides, an α-MSH derivative [147] NAP-NS1(d) 
peptide was conjugated with a trialkyltin group and radiolabeled as well.  For the 
labeling of other molecules, various of trialkyltin based precursors (e~i) were 
synthesized. 197(m)Hg-MIBG(e) has been labeled for the purpose of neuroendocrine 
tumors detection [148]. Sunitinib as a receptor tyrosine kinase inhibitor [149] could be 
radiolabeled with 197(m)Hg (f) for renal cell carcinoma (RCC) and gastrointestinal stromal 
tumor (GIST) detection. Besides,197(m)Hg labeled agmatine(g) for inflammatory and 
neurological scan, 197(m)Hg-CSN(h) for reactive oxygen species (ROS)/superoxide 
detection and 197(m)Hg labeled PSMA(i) as prostate-specific membrane antigen Inhibitor 
for prostate cancer detection. Herein, several small targeted molecules precursors 
were selected as representatives for 197(m)Hg labeling among the broader studies in this 
work. 
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Figure 3.47: Scheme of 197(m)Hg labeling with specific targeted molecules with trialkyltin precursors. 
 
 
3.5.1 Radiosynthesis of 197(m)Hg labeled agmatine compounds ([197(m)Hg]35 and 
[197(m)Hg]36). 
 
Agmatine is naturally created from the amino acid arginine by decarboxylation and it 
has been shown to exert modulatory action at multiple molecular targets: it shows 
strong relationship with ion channels and polyamine metabolism; it stimulates the 
production of muscle enhancing nitric oxide; it can influence brain function as a 
neurotransmitter and neuromodulator as well [150]. Additionally, it has also shows 
promise in reducing drug addiction, neuropathic pain. Considering the advantages of 
197(m)Hg for the combination of diagnostics and therapy (theranostics) purposes in 
comparison with some other radionuclides，197(m)Hg labeled agmatine offers a new 
approach to provide bases for further research on the mechanism of these actions as 
potential applications. 
 
3.5.1.1 Radiosynthesis of asymmetric 197(m)Hg labeled agmatine ([197(m)Hg]35) 
The agmatine ligands: 1-(4-(((4-(trimethylstannyl)benzoyl)oxy)amino)butyl)guanidine 
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activity. The radiolabeling procedures were carried out at 10, 30 and 50% ethanol of 
resulting solution, respectively. The labeling yields did not improve (10%~30%). In 
conclusion, the preparation of [197(m)Hg]35 with low percentage ethanol as solvent was 
not usable. For improving the results, DMSO was tested as alternative solvent with 10, 
30 and 50% aqueous solutions. The reaction mixture with 50% DMSO group showed 
best result in respect to yield (~40%), which is rather low. Changing of temperatures 
and pH, higher labeling efficiency was not achieved as expected either. The reason of 
poor efficiency for 197(m)Hg labeled agmatine complex could probably because the 
access of trimethyltin- are weaker than tributyltin- group as the donor in the reaction 
mixture.  
For the purpose of animal experiment, the highest radiochemical efficiency was 
achieved only as described in 70% ethanol solution above. Thus, sample needs to be 
purified after evaporated under a stream of Argon. For the removal of organic solvent, 
sample was evaporated under a stream of Argon. However, measured by dose 
calibrator, the remained activity was 10.25 MBq (total ~70 MBq) which showed a great 
activity loss after evaporation.  
 
 
3.5.1.2 Purification test of [197(m)Hg]35 using C18 Sep-Pak cartridges  
Purification of [197(m)Hg]35 of 3.5.1.1 was performed with Sep-Pak® C18 cartridges. 
This method is commonly used to get various radiotracers ready for injection. Following 
steps were necessary:  
1. Attach a syringe and equilibrate the C18 cartridges column before sample loaded.  
2. Flush the cartridge with 10 ml of deionized water first, then flush with 10 ml of 
absolute ethanol. 
3. Remove the left ethanol inside the column by flushing with 50 ml of deionized water. 
4. Dry the cartridge under a stream of Argon or N2 and equilibration finished. 
5. Measure the activity of [197(m)Hg]35 sample (10.25 MBq) with a dose calibrator 
(Isomed 2000, Dresden, Germany). 
6. Add the sample onto the Sep-Pak column and wash the sample with 10 ml of 
deionized water, which was intended to wash out the sodium salts.  
However, the washed-out fraction was collected and measured with activity of 5.8 MBq, 
which indicated the generated of 197(m)Hg contaminants in water fraction.  
 
Only 43% of labeled [197(m)Hg]35 were found adsorbed in the cartridge. Next steps: 
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1. Elute the rest of labeled sample with 0.5 ml of 50% ethanol and measure the activity 
(only 0.15 MBq). 
2. Elute the cartridge again with 0.5 ml of 100% ethanol, the activity of this washed 
fraction was only 0.85 MBq. 
3. The rest activity was found remaining on the cartridge, which indicated that labeling 
products have strong interaction with the cartridge’s inner surface or contents.  
The results of purification attempt show that the separation of the labeling product 
[197(m)Hg]35 was not successful, further work could be focused to separation by semi-
preparative HPLC. 
 
 
3.5.1.3 Radiosynthesis of symmetric 197(m)Hg labeled agmatine complex ([197(m)Hg]36) 
Symmetric 197(m)Hg labeled agmatine complex ([197(m)Hg]36) was prepared as well 
(Figure 3.50 a). Into a glass vial, 20 μl (~30 MBq) [197(m)Hg]HgCl2 was added to 1 M 
MES buffer containing 50 μl (1mg/ml) 33. The resulting mixture was incubated at 50 °C 
for 60 min in 70% ethanol solution.  The extent (RCY) of labeling was monitored via 
radio-TLC. However, most of activity remained at starting point for SG and RP-18 
plates which is difficult for the determination of RCY. To confirm the RCY of 
[197(m)Hg]36, two other TLC plates were turned to use: plates coated with neutral 
aluminum oxide with a solution of CH3CN/H2O/TFA acid 90/10/0.1 (v/v/v) as mobile 
phase (Method 3); cellulose plate with a solution of CH3CN/H2O/TFA acid 90/10/0.1 
(v/v/v) as mobile phase (Method 4). 
Pure [197(m)Hg]HgCl2 was determined with these plates firstly (Figure 3.50 b). On 
aluminum oxide plate: ~50% of activity remained at starting point and the rest moved 
with solvent front. On cellulose plate: nearly all [197(m)Hg]HgCl2 remained at starting 
point. In the study, pure [197(m)Hg]HgCl2 shows two peaks on aluminum oxide plate. 
Because different forms of [197(m)Hg]Hg2+ ions exist in the organic solvent. The exact 
formations of the two peaks are still unclear. 
For the [197(m)Hg]36 analysis (Figure 3.50 c), on aluminum oxide: [197(m)Hg]36 at 
Rf~0.75; on cellulose plate: [197(m)Hg]36 moved with the solvent front.  
NS3 soaked aluminum oxide was developed for the stability study. As seen in Figure 
3.50 c blue, the transchelation was observed at Rf~0.3 with low counts. The main 
activity still remained at same position which indicated that [197(m)Hg]36 exhibited high 
stability.   
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    33                                                                    [197(m)Hg]36 
  
Figure 3.50 a: Radiosynthesis scheme of [197(m)Hg]36 
 
Figure 3.50 b: Radio-TLC analysis of [197(m)Hg]HgCl2 with aluminum oxide (left) and cellulose plate (right) 
mobile phase: CH3CN/H2O/TFA acid 90/10/0.1 (v/v/v). 
 
Figure 3.50 c: Radio-TLC analysis (blue) of [197(m)Hg]36 with aluminum oxide (left) and cellulose plate 
(right) mobile phase: CH3CN/H2O/TFA acid 90/10/0.1 (v/v/v). Stability studies (blue) were performed with 
NS3 soaked plates (same mobile phase). 
 
Excess of ethanol was evaporated from resulting solution under a stream of Argon for 
the preparation of animal imaging using [197(m)Hg]36 complex. The most of activity 
(18.8 MBq) was measured before evaporation by dose calibrator (Isomed 2000, 
Dresden, Germany). Surprisingly, the remained activity was only 1.65 MBq in solution 
after evaporation, which showed a 98.25% of activity loss. Therefore, the 
radiosynthesis of [197(m)Hg]36 was failed at a preparative level and hard for preclinical 
studies.  
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3.5.2 Radiosynthesis of asymmetric 197(m)Hg labeled PSMA compound 
([197(m)Hg]39). 
Prostate specific membrane antigen (PSMA) is overexpressed on prostate cancer cells 
in proportion to the stage and grade of the tumor progression, especially in androgen-
independent, advanced and metastatic disease, rendering it a promising diagnostic 
and/or therapeutic target. From the perspective of nuclear medicine, PSMA-based 
radio-ligands may significantly impact the management of patients who suffer from 
prostate cancer. For that purpose, chelator-based PSMA-specific ligands have been 
labeled with various diagnostic/therapeutic radionuclides for SPECT or PET studies 
[151-153]. For theranostic purposes a 197(m)Hg labeled PSMA could be of interest. Thus, 
a novel trialkyltin based PSMA-specific ligand was designed for a 197(m)Hg labeling 
study. The structure of trialkyltin based PSMA Inhibitor (37) is shown in Figure 3.51a. 
For the synthesis of 37 10, three tert-butyl ester protecting groups were introduced for 
the protection of carboxyl groups during preparation process to avoid the activated 
amino bond with the undesired carboxyl group of the peptide. Considering the 
decomposition of trialkyltin- group in acidic environment, the de-protection must be 
done after the labeling. 
 
The labeling study was conducted with similar procedure as Method C (5.5.3). The 1st 
step was the radiosynthesis of [197(m)Hg]PSMA-HgCl ([197(m)Hg]38). Briefly, 20 μg PSMA 
precursor (37) (1mg/ml solution in ethanol) was added to 50 μl 10 MBq [197(m)Hg]HgCl2 
dissolved in 0.2 M HCl solution. The effect of excess HCl (acid environment) was not 
only helpful to avoid the formation of diphenylmercury derivatives, but also for the 
removal of tert-butyl ester protecting groups. To this solution, 70 μl ethanol was added 
to keep 50% ethanol in the final volume. After incubation at 50 °C for 3 h, the extent 
(RCY) of [197(m)Hg]38 labeling was determined using radio-TLC. On Silica Gel plate 
(Method 1: see 3.3.1): [197(m)Hg]38 moved to the solvent front. On RP-18 plate (Method 
2: see 3.3.1): [197(m)Hg]38 remained at Rf~0.85. 
 
 
                                                 
 
10 The synthesis was performed by Mrs. Bianca Kreisl, Institute of Radiopharmaceutical Cancer Research, 
Helmholtz-Zentrum Dresden-Rossendorf. 
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Three strategies were tested for the improvement of deprotection in the 1st step:  
1. Mild reagent ascorbic acid was supposed to be the optimal for de-protection process 
firstly for that purpose. 500 μl (1mg/ml stock solution) ascorbic acid solution was added 
into the resulting mixture of 1st step. However, the analysis by radio-HPLC still showed 
a low de-protection yield of [197(m)Hg]38 after radiosynthesis.  
2. Higher concentrations (1 M and 6 M) of hydrochloric acid were performed in the 
radiosynthesis of 1st step for de-protection process. The labeling procedure is similar as 
above, but with an extension of reaction time (12 h) and lower temperature (25 °C) to 
prevent the interference of 37 decomposition. However, radio-TLC showed that desired 
labeling product wasn’t obtained. Obviously, the tin precursor (37) might have been 
decomposed in high acid concentration.  
3. As the most commonly used strategy, TFA was also applied for the removal of the 
ester protecting groups. 1~2 ml TFA were added into the resulting solution of 1st step. 
The mixture was then incubated at room temperature for another 1 h. The resulting 
solution was evaporated to dryness under a stream of nitrogen before monitored by 
radio-HPLC. However, [197(m)Hg]38 as labeling product was also volatile substance 
which was volatilized together with TFA during evaporation. 
To conclude, future work should be focused to the semi-preparative HPLC. 
 
 
3.5.3 Radiosynthesis of [197(m)Hg]41 for the detection of reactive oxygen species 
 
Reactive oxygen species (ROS) play crucial roles in the pathogenesis of may disease 
states and drug toxicities which is an urgent need for a successful development of 
detection tools. According to the report from x.z. Zhang et al. [154], a novel precursor 
40 (CSN) was synthesized 11  and labeled with radioactive iodine as the superoxide 
sensitive polarity-inversing tracer: [125I]5-iodo-3-oxo-3H-spiro[isobenzofuran-1,9’-
xanthene]-3’,6’-diylbis(trifluoromethane sulfonate) (125I-CSN). 125I-CSN validated as a 
potential SPECT probe able to be trapped and accumulated in the superoxide rich cells 
for superoxide semi-quantitative detection. A kinetic study of the 125I-CSN compound 
showed a rapid and selective oxidation by superoxide. This was also confirmed by 
                                                 
 
11  Dr. Xianzhong Zhang and his student Lumei Huang (Xiamen University, China) synthesized the 
precursor and authorize us for the 197(m)Hg labeling study in this work. 
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SPECT imaging studies and bio-distribution studies of arthritis mice on organs 
subsequently.  
In the frame of the present work a specific trialkyltin precursor 40 could also be radio-
labeled with 197(m)Hg for the detection of superoxide. The synthetic pathway and 
labeling scheme are shown in Figure 3.54 a.   
After determination of the purity of 40 with HPLC, the precursor 40 was labeled with 
197(m)Hg at pH 1, the extent (RCY) of labeling was examined via radio-TLC and radio-
HPLC (Figure 3.54 b). The product peak was found retained at 16.5 min for precursor 
40 and 15.5 min for [197(m)Hg]41. 
 
  
 
Figure 3.54 a: synthesis scheme of CSN ligand (40) and Radiosynthesis scheme of [197(m)Hg]41 
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semi-preparative HPLC may be useful. 
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4 Conclusions 
197(m)Hg is a potential radionuclide for both: SPECT imaging and therapeutical use 
(theranostics). Therefore, the motivation of this work was to develop novel 197(m)Hg 
labeling tracers with promising radiochemical behaviors and biological behaviors for 
theranostic studies. On the basis of this purpose, we succeed in producing and 
separating n.c.a. [197(m)Hg]HgCl2 and developing several promising ligands which 
formed stable 197(m)Hg labeled compounds. The achievements of this work are as 
follows: 
 
 
4.1 Radiomercury production in sufficient quantity and quality 
Two approaches (proton or deuteron irradiation) are both available as a production 
routine for the 197(m)Hg production. Production of 197(m)Hg by proton irradiation shows 
lower yield and low percentage of isomeric state. The activity level is sufficient for 
analytical study and labeling studies with small scale. Besides, the cyclotron facility 
located in Helmholtz-Zentrum Dresden-Rossendorf is a convenient site for target 
irradiation which is economical, time saving and safe. In contrast, deuteron irradiation 
produces high activity but a high percentage of isomeric state 197mHg, which is suitable 
for preclinical studies. The higher activity concentration exhibits advantages: not only 
easier to obtain 197(m)Hg starting activity with higher effective molar (specific) activity but 
also easier for handling the pH and excess of salts in labeling procedures. In particular, 
in the process of 197(m)Hg antibody (C225) labeling, the 197(m)Hg labeled antibody still 
remained on a high activity and high effective molar (specific) activity level after 
purification. 
 
 
4.2 Development of a reliable method for Hg/Au separation  
High purity and high Am (As) of n.c.a.197(m)Hg is the basic guarantee of successful 
labeling experiment, which needs the development of a simple, fast, efficient, reliable 
and for application available method for 197(m)Hg separation from gold target. We 
checked different methods for mercury separation, including metal sublimation, 
extraction by organic solvents and extraction by resins. Two approaches were applied 
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for Hg/Au separation: solvent extraction with MIBK and liquid solid extraction with LN 
resin.  
 
Extraction with MIBK shows medium efficiency and provides an acceptable purity. 
Comparing with MIBK, mostly used LN resin-based method shows highest efficiency, 
provides highest radionuclide purity and allows to collect higher 197(m)Hg activity in a 
small volume.  Moreover, it is characterized by a simple operating procedures and 
short total processing time during separation. However, the drawback of both 
approaches is the loss of 197(m)Hg in the last evaporation step. Therefore, the 
development of a novel method for the removal of excess HCl is still urgent needed.  
 
 
4.3 Development of application available 197(m)Hg labeling units 
The main goal of this work is the development of novel 197(m)Hg labeled ligands for the 
further theranostic studies. Many factors need to be taken into consideration for the 
design of ligands (chelators or binding moieties) before a specific target conjugation is 
useful. In particular, radiosynthesis, solubility, stability and selectivity are the most 
critical issues: 
1. Radiosynthesis is the premise for each radiopharmaceutical. Normally, radiolabeling 
studies should be carried out to find the best labeling efficiency at several fixed given 
conditions. For the labeling procedure, a mild reaction condition (low temperature, short 
time, etc.) is always the optimal strategy for applications. Harsh conditions might not 
only increase the risk of decomposition or sublimation of 197(m)Hg labeled agents, but 
also lead to a poor labeling efficiency. 
2. Stability, especially in vivo stability is one of the most important (radiochemical) 
properties for the chelating/binding unit. Radiopharmaceuticals are administered via 
intravenous injection into the blood stream, the concentration of the tracers may 
become so low that dissociation of the 197(m)Hg from chelating/binding units will 
eventually become favored. Thus, the injected radionuclide dose is evenly distributed in 
many other organs and tissues. A problem maybe the large number of thiols (e.g. free 
cysteine and peptides and proteins) in the blood stream and other organs in human 
body. As 197(m)Hg labeled units are weak against thiols, 197(m)Hg would likely form 
undesired trans-chelates with competing thiols. Besides, 197(m)Hg labeled agents require 
high thermodynamic stability and kinetic inertness for animal studies. 197(m)Hg labeled 
compounds with weak thermodynamic stability would also significantly increase the 
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accumulation of radioactive substances in non-target organs. Therefore, under in vivo 
conditions, 197(m)Hg labeled units must form a stable structure to retain its chemical 
integrity against competing thiols and to keep its structure. 
3. Solubility is probably the most critical issues in this case. In the preparation of 
197(m)Hg labeled products, the poorly soluble ligands might not only result in the 
miscarriage of radiosynthesis, but also leads to strong interactions with the surface of 
vials or syringe which would be difficult for handling and for animal studies because of 
high lipophilicity. Furthermore, the injected 197(m)Hg tracers may exhibit unfavorable in 
vivo behavior. 
4. Selectivity (specifity) of chelators is also a critical issue. A poorly selective chelator 
may have strong interactions on other metal ions. Luckily, the high purity of 
[197(m)Hg]HgCl2 after separation (low Au3+ concentration) excludes the interaction with 
Au3+, which have strong affinity toward sulfur-based chelators.  
These critical issues were the main criterion for the development of newly designed 
chelating/binding units. 
 
There are mainly two different approaches for 197(m)Hg labeling/chelating in this work. 
Mercury shows strong ability on chelating of thiols, dithiols, disulfides, sulfur based and 
other sulfur rich interacting ligands. First classified ligands are based on Hg-S bonds 
(other oxygen group elements as alternative), which forms 197(m)Hg-S based 
compounds. The second approach is based on the unique mercury chemistry: direct 
coupling of a Hg-C bond, called Hg-organometallics. In addition, there also exists a 
‘side way’ of these two approaches in between (S-Hg-C bond).  
At initial stage, series of 197(m)Hg-S based compounds were developed with great 
expectation. These chelators were originally derived from chemosensors used for 
quantification of mercury ions which exhibited high selectivity and sensitivity towards 
Hg2+ in aqueous solution against a background of competing agents (metal ions). 
However, after synthesized and radiolabeled with 197(m)Hg, the evaluation studies of 
these Hg-S bond compounds showed critical results, such as low RCY, poor solubility 
and unstable against other competing thiols. 197(m)Hg-bipodal thiocarbamate complexes 
([197(m)Hg]4) were achieved with low labeling efficiency due to poor solubility. Due to 
considerable gaps in knowledge surrounding the biological behavior/actions of 197(m)Hg 
labeled tracers in body, thiolate based [197(m)Hg]2 was selected for SPECT imaging 
studies in rats. Compared with only [197(m)Hg]HgCl2, [197(m)Hg]2 showed a similar high 
kidney uptake which indicated the high degree of instability and the release of the 
197(m)Hg2+ ions. The radiolabeling study with NS2 chelating motif 5 ([197(m)Hg]6) and NTe2 
chelating motif 6 ([197(m)Hg]8) showed that other oxygen group element Tellurium based 
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motif 5 did not show a strong binding towards 197(m)Hg compared with the Sulfur based 
motif 6.  
To conclude, all of these Hg-S bond compounds showed a weak stability against 
cysteine together with weak solubility. Besides, 197(m)Hg was also labeled with 
commercial available N-bearing macrocyclic ligands: bispidine and DiAmSar (Hg-N 
bond), which showed weak stability because of weak Hg-N coordination. Altogether, 
they are all not suitable for radiopharmaceutical applications. 
 
In this work, we succeed in developing a new approach based on Hg-organometallics: 
[197(m)Hg]phenyl-HgCl and ([197(m)Hg]10) and [197(m)Hg]diphenyl-Hg ([197(m)Hg]11). They 
were radiosynthesized with tributyl(phenyl)stannane (9) via electrophilic aromatic 
substitution, which showed great labeling efficiency and high stability against 
competing thiol agents like cysteine. Moreover, an imidazole derivative precursor (12) 
showed great potentials because of mild radiolabeling conditions of [197(m)Hg]13 and 
[197(m)Hg]14 together with high labeling efficiency and high effective Am (As) in 
comparison with the unmodified [197(m)Hg]10 and [197(m)Hg]11, this may be due to the 
better solubility in the reaction mixture. In this regard, radio-TLC, radio-HPLC, together 
with other methods were performed for the examination.  
Interestingly, in the reaction with trialkyltin-precursors, different products were formed 
by the variations of pH. At pH 1, [197(m)Hg]phenyl-HgCl derivatives (Hg:C=1:1 
compounds) were obtained; While, at pH 6, [197(m)Hg]diphenyl-Hg derivatives (Hg:C=1:2 
compounds) were formed (Figure 4.1). The effect of pH was utilized for the 
radiosynthesis of different 197(m)Hg-chelating units.  
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Figure 4.1: Radiosynthesis scheme of symmetric and asymmetric 197(m)Hg labeled compounds with 12 and 
25 ([197(m)Hg]13, [197(m)Hg]14, [197(m)Hg]27 and [197(m)Hg]42). 
 
Based on this, we also developed pathways to different asymmetric 197(m)Hg-
compounds and made some success (Figure 4.1):  one [197(m)Hg]phenyl-HgCl derivative 
(Hg-C: specific targeted molecule) could conjugate another molecule (Hg-S: tuning of 
solubility and excretion behavior) to facilitate multiple functionalization. Given this, 
[197(m)Hg]13 was conjugated with dithiocarbamate (25) and asymmetric [197(m)Hg]27 
was obtained. To validate the results, the non-radioactive substance [natHg]27 was 
prepared and the structure confirmed; it serves as reference compound for 
radiochemical chromatographic investigations. 
To investigate the radiochemical and radiopharmacological behaviors of asymmetric 
dithiocarbamate arylmercury compounds, the most promising asymmetric radiolabeled 
units [197(m)Hg]28 and [197(m)Hg]29 compounds were radiosynthesized and selected for 
further SPECT imaging studies. They both performed a good solubility and the injected 
dose excreted via the renal system and intestine.  
Additionally, N-heterocyclic carbene (18) was synthesized and labeled with 197(m)Hg 
([197(m)Hg]19), [197(m)Hg]19 was not stable against thiols and the Hg-C bond was weaker 
than [197(m)Hg]diphenyl-Hg derivatives. 
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4.4 Outlook to 197(m)Hg labeled small targeting molecules. 
Finally, several small targeting molecules are selected and prepared as trialkyltin 
precursors representatives. These agents were labeled with 197(m)Hg and formed 
[197(m)Hg]35, [197(m)Hg]36, [197(m)Hg]39 and [197(m)Hg]41. However, the radiolabeling 
procedure was somewhat distinct from the promising chelating pattern [197(m)Hg]27, 
which is probably because the structures of targeting moieties affect the trialkyltin 
substituents in the reactions. 
 
In summary, stable asymmetric dithiocarbamate aryl-mercuries seem to open up 
tremendous opportunities owing to the relatively high stability and water solubility. The 
future developments should continue concentrate on 197(m)Hg labeling with specific 
targeted molecules.  
Meanwhile, further optimization of labelings and SPECT imaging studies are under 
investigation.  
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5 Experimental part 
5.1 Chemicals and materials 
5.1.1 Chemicals  
All chemicals were purchased commercially and used without further purification, if not 
mentioned otherwise. Important chemicals used in the work were listed in Table 5.1. 
 
Chemical Manufacturer 
1-Aza-15-crown-5 Alfa Aesar 
1,3-Bis(bromomethyl)benzene Sigma-Aldrich 
1,4-Dioxane Sigma-Aldrich 
2-(N-morpholino)ethanesulfonic acid (MES) Fluka 
2-Propanol Sigma-Aldrich 
4-Aminobenzoic acid Sigma-Aldrich 
4-(Dimethylamino)-pyridine Aldrich 
4,4′-Bis(dimethylamino)thiobenzophenone (TMK) Sigma-Aldrich 
9-Aminodecanoic acid Alfa Aesar 
11-Aminoundecanoic acid Sigma-Aldrich 
11-Azido-3,6,9-trioxaundecan-1-amine Carl-Roth 
Acetonitrile, HPLC grade VWR 
Ammonium acetate (NH4OAc) Fluka® 
Bovine serum albumin  Sigma-Aldrich 
Carbon disulfide Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) VWR 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Diethanolamine (DEA or DEOA) Thermo-Fisher  
Diethyl ether Sigma-Aldrich 
Dichloromethane (DCM) Sigma-Aldrich 
Ethanol, absolute VWR 
Hydrochloric acid Sigma-Aldrich 
Methanol, HPLC grade Fisher Scientific 
Mercury(II) chloride Sigma-Aldrich 
N,N-Dimethylformamide(DMF), absolute Sigma-Aldrich 
Piperidine, 99% Sigma-Aldrich 
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Potassium hydroxide (KOH) Sigma-Aldrich 
Sodium carbonate (Na2CO3) Carl-Roth 
Sodium chloride (NaCl) Fluka® 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich 
Sodium diethyl-dithiocarbamate (25) Sigma-Aldrich 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sodium tetraphenylborate Sigma-Aldrich 
Sodium tetrakis(2-thienyl)borate Sigma-Aldrich 
Triethylamine Sigma-Aldrich 
Tributyl(phenyl)stannane Sigma-Aldrich 
Trifluoroacetic acid (TFA), >99,9% Alfa Aesar 
 
Table 5.1: List of chemicals 
 
5.1.2 Buffers  
The composition of self-prepared buffers is specified in each section and prepared 
according to the instruction (Table 5.2). 
 
Buffer Composition 
50 mM Ammonium 
acetate Buffer 
3.854 g of NH4OAc 
9.045 g NaCl (0.9%) 
Adjust pH to 9.0 with 1 M NaOH and make final 
volume up to 1 L with H2O 
0.1 M MES Buffer 
1.0663 g MES monohydrate 
Adjust pH to 6.0 with 1 M NaOH and make final 
volume up to 50 ml with H2O 
0.2 M MES Buffer 
2.1326 g MES monohydrate 
Adjust pH to 6.0 with 1 M NaOH and make final 
volume up to 50 ml with H2O 
1 M MES Buffer 
10.663 g MES monohydrate 
Adjust pH to 6.0 with 30% NaOH and make final 
volume up to 50 ml with H2O 
 
Table 5.2: List of buffers 
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5.2 Analytical Methods 
5.2.1 Nuclear magnetic resonance spectroscopy 
1H-NMR and 13C spectra were recorded on a 400 MHz Varian Inova 400 spectrometer. 
Chemical shifts were recorded on a δ scale in parts per million (ppm). The samples 
were dissolved in deuterated solvents as indicated. Tetramethylsilane (TMS) was used 
as an internal calibration standard. CDCl3 (δ 7.26 ppm) or D2O (δ 4.79 pm) were used 
for calibration standard for 1H spectra. The abbreviations used to describe the 
resonances are: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), 
m (multiplet), and br (broad). The data analysis was done using Mestronova software 
(version 12.0). 
 
5.2.2 UV-Vis Spectroscopy 
UV-Vis spectroscopy was conducted on Specord® S50 from Analytik Jena (Germany). 
The samples were measured on quartz micro cuvettes (d=1cm) with 400-500 μl with a 
wavelength range from 190-1100 nm. The standard calibration curves and the molar 
extinction coefficient were calculated using the Beer-Lambert equation: A= ε x l x c 
where A is the absorbance at λmax, ε denotes the extinction coefficient, c denotes the 
concentration and l denote the path length of the cuvette (1 cm). The measurements 
were set relative to the blank solution (reference). Data were processed using the 
WinASPECT® software. 
 
5.2.3 Instant thin-layer chromatography (ITLC) 
Thin Layer chromatography was conducted on TLC Silica gel 60 RP-18 F254S plates 
from Merck (reverse phase, RP-TLC) using DCM: MeOH (19:1, v: v) as mobile phase. 
UV lamp at 254 nm was used for analysis. 
 
 
5.3 Radio-analytical Methods 
5.3.1 Radio-Thin Layer Chromatography (Radio-TLC)  
Instant thin-layer chromatography (ITLC) is also a quick method of assessing the 
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radiochemical purity of radiolabeled complexes, which also called Radio-Thin Layer 
Chromatography (radio-TLC). Radiochemical analysis of the yields was determined 
using different stationary phase (TLC plates) and eluent systems (Mobile phase or 
solvent). The implementation of instant thin-layer chromatography was carried out 
vertically in an ITLC chamber saturated with mobile phase. The analysis was 
performed subsequently using activity thin layer chromatography detector RITA 
(Raytest). The applied TLC systems are listed in Table 5.3: 
 
Method TLC-Plates  Mobile Phase 
1 iTLC-SG CH3CN/acetic acid 100/1 (v/v) 
2 RP-18 Plates (Merck) CH3CN/H2O/TFA acid 90/10/0.1 (v/v/v) 
3 Neutral Aluminum Oxide (Alox) CH3CN/H2O/TFA acid 90/10/0.1 (v/v/v) 
4 Cellulose CH3CN/H2O/TFA acid 90/10/0.1 (v/v/v) 
 
Table 5.3: Radio-TLC methods 
 
5.3.2 Radio-High performance liquid chromatography (Radio-HPLC) 
For the analysis of dithiocarbamate arylmercury corresponding study, following devices 
were used: PerkinElmer series 200 HPLC pump; PerkinElmer UV/VIS 
spectrophotometric detector LC290 with detection at 220 and 254 nm; Raytest Ramona 
radioactivity detector; TotalChrom Navigator version 6.2.1 was used for data 
processing and analysis.  Zorbax C18 column with inner diameter of 8 mm was used 
and the injection volume was 0.5 ml. The mobile phase was solvent A: water with 0.1% 
TFA and solvent B: acetonitrile with 0.1% TFA. Two methods were performed in the 
study. For the 25 min method, HPLC gradient of B phase: in 0~20 min from 45% to 
80%, in 20~25 min from 80% to 100%. For the 41 min method, HPLC gradient of B 
phase: in 0~30 min from 10% to 60%, in 30~40 min from 60% to 95%, 40~41 min from 
95% to 10%. 
 
Surprisingly, unmodified or unlabeled [197(m)Hg]HgCl2 remains completely on the Zorbax 
RP-C18 column sometimes during radio-HPLC study. It could be used for confirming 
retention time of 197(m)Hg labeling agents, but not for the determination of unlabeled 
[197(m)Hg]HgCl2 in resulting solution. While Phenyl-henxl column was found able to 
detect the unmodified [197(m)Hg]HgCl2 which could be used for the determination of 
radiochemical purity of 197(m)Hg-complex. Thus, with 197(m)Hg labeled 40 (CSN) as 
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example, the analysis of other 197(m)Hg labeled targeting molecules could be performed 
with Phenyl-Hexyl column in high performance liquid chromatography plant from Jasco 
LC-4000 Series Systems (Jasco International Co. Japan). following devices were used: 
Jasco PU4180 HPLC pump; Jasco MD-4010 PDA detector; Jasco LC-NetII/ADC 
interface box; Raytest Ramona radioactivity detector; Chrom Navigator 2.1. Kromasil 
Eternity Phenyl-Hexyl column with inner diameter of 8 mm was used. The mobile 
phase was solvent A: water with 0.1% acetic acid and solvent B: acetonitrile with 0.1% 
acetic acid. For the 30 min method, HPLC gradient of B phase: in 0~20 min from 80% 
to 90%, in 20~25 retained 90%, in 25~27 min from 90% to 80%, in 27~30 min from 
90% to 80%.  
 
The Kromasil Eternity Phenyl-Hexyl phase provides an alternative selectivity compared 
to a traditional alkyl chain phase or a polar embedded phase. Unlike unmodified 
[197(m)Hg]HgCl2 remains completely on the commonly used RP-C18 column, Phenyl-
Hexyl column can be used to confirm contaminants or free radiometal ions 197(m)Hg. 
Moreover, it saves more time especially when the analysts of interest contain an 
aromatic ring in the separation and analysis. Including excellent peak shapes for 
compounds under both low and high pH conditions (stable between pH 2 to pH 12). 
Not to mention Phenyl-Hexyl offers minimum bleed for LC/MS applications either. In a 
word, it leads to the increase efficiency and more useful in the separations of 
aromatics. 
 
Column RP-C18  Phenyl-Hexyl 
Functionalizing the silica RP-C18 Phenyl-Hexyl 
[197(m)Hg]HgCl2 analysis not available available 
Aromatics analysis good suitable 
Available at pH Range 1 ~ 12 2 ~ 12 
 
Table 5.4: Comparisons of columns for radio-HPLC analysis 
 
5.4 Synthesis and characterization of dithiocarbamate derivatives 
5.4.1 Synthesis of Dipotassium 11-(carbodithioatoamino)dodecanoate  (20) 
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Potassium hydroxide (KOH 0.65 g, 10.2 mmol) was dissolved in 70 ml of water. To the 
resulting solution, 11-aminoundecanoic acid (1.00 g, 4.64 mmol) and acetone (30 ml) 
were added under stirring. The reaction mixture was cooled at 0 °C. Keep stirring 15 
minutes at 0 °C and carbon disulfide (0.50 ml, 6.37 mmol) was then added dropwise 
under stirring. The resulting yellow solution was kept stirring overnight at 0 °C and then 
evaporated under reduced pressure to give a pale yellow solid. The combined solids 
were then washed with 100 ml CH2Cl2, 100 ml ethanol and 50 ml diethyl ether 
separately. Eventually, 0.96 g 20 was collected as a colorless solid (Yield: 75%). 1H 
NMR (400 MHz, D2O) δ: 3.43 – 3.29 (m, 1H), 2.10 – 1.96 (m, 1H), 1.43 (dt, J = 14.8, 
7.3 Hz, 2H), 1.18 (d, J = 7.9 Hz, 6H). 13C NMR (100 MHz, D2O) δ: 209.6, 184.3, 48.1, 
37.6, 28.7, 28.6, 28.6, 28.5, 28.4, 27.6, 26.1, 25.9. 
 
Notes: Stability of dithiocarbamates achieved can be very disappointing since the 
dithiocarbamates may decompose, particularly upon heating. Significantly, 
decomposition yields are usually not given in the literature, so the products should be 
kept at a lower temperature.  
 
5.4.2 Synthesis of Dipotassium 9-(carbodithioatoamino)dodecanoate  (21) 
 
 
21 was obtained with similar procedure as described in 5.4.1. The reaction mixture was 
containing: 9-aminodecanoic acid (0.80 g, 5.00 mmol), potassium hydroxide (KOH 0.65 
g, 10.2 mmol), carbon disulfide (0.50 ml, 6.37 mmol), 30 ml acetone and 70 ml of 
water. Eventually, 1.1 g of 21 as light-yellow solid was obtained. (Yield: 80%). 1H NMR 
(400 MHz, D2O) δ: 4.66 – 4.60 (m, 11H), 3.50 (q, J = 7.1 Hz, 1H), 3.34 (t, J = 7.1 Hz, 
5H), 2.02 (dd, J = 8.0, 7.0 Hz, 5H), 1.42 (tdd, J = 14.0, 10.9, 7.2 Hz, 10H), 1.23 – 1.09 
(m, 16H), 1.03 (td, J = 7.1, 4.5 Hz, 2H). 13C NMR (100 MHz, D2O) δ: 209.6, 184.2, 
48.1, 37.6, 28.6, 28.2, 27.6, 25.9, 25.8. 
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5.4.3 Synthesis of Potassium trioxaundecan-dithiocarbamate derivative (22) 
 
 
22 was obtained with similar procedure as described in 5.4.1.  11-azido-3,6,9-
trioxaundecan-1-amine (48.23 mg, 0.22 mmol), potassium hydroxide (KOH 25 mg, 0.45 
mmol), carbon disulfide (18 μl, 0.22 mmol) was added and eventually, 40.12 mg of 22 
as white solid was obtained (Yield: 70%). The NMR was consistent with the assigned 
structure of 22. 1H NMR (400 MHz, D2O) δ: 4.51 – 4.37 (m, 1H), 3.78 – 3.72 (m, 1H), 
3.67 – 3.55 (m, 16H), 3.38 (t, J = 4.9 Hz, 2H). 13C NMR (100 MHz, D2O) δ: 211.8, 72.2, 
71.6, 69.2, 68.7, 68.2, 60.3, 50.1, 47.2. 
 
5.4.4 Synthesis of Potassium 1-aza-15-crown-dithiocarbamate derivative (23) 
 
 
23 was obtained with similar procedure as described above (5.4.1). 1,4,7,10-tetraoxa-
13-azacyclopentadecane (112.0 mg, 0.51 mmol), potassium hydroxide (KOH 56 mg, 1 
mmol), carbon disulfide (50 μl, 0.64 mmol) was added and eventually, 75.5 mg of 23 as 
light-yellow solid was obtained (Yield: 65%). The NMR was consistent with the 
assigned structure of 23. 1H NMR (400 MHz, D2O) δ: 4.31 (t, J = 6.1 Hz, 2H), 3.95 (t, J 
= 6.1 Hz, 2H), 3.74 (d, J = 3.2 Hz, 6H). 13C NMR (100 MHz, D2O) δ: 211.1, 69.7, 69.6, 
69.2, 68.1, 56.0. 
 
 
5.4.5 Synthesis of Sodium bis(2-hydroxyethyl)dithiocarbamate (24) 
 
 
In a 100ml round-bottom flask fitted with an overhead stirrer, inert gas inlet, and 
addition funnel dissolve 4.0 g (0.1 mol) of sodium hydroxide and 10.5 g (0.1 mol) of 
diethanolamine in 40 ml of methanol.  Purge with inert gas Argon and cool to below 
Experimental part 
__________________________________________________________________________________________________________ 
131 
5 °C. Add 11.4 g (0.15 mol) of carbon disulfide dropwise while keeping the temperature 
below 5 °C. After one night reaction, remove the methanol with a rotary evaporator at a 
bath temperature of 35 °C. To crystallize the viscous liquid, add 400 ml of 2-propanol 
and mix vigorously. Filter and dry under vacuum at ambient temperature. 15.4 g of 24 
was obtained eventually (Total Yield: 76%). The NMR was consistent with the assigned 
structure of 24.1H NMR (400 MHz, D2O) δ: 4.79 (s, 2H), 4.29 (t, J = 6.0 Hz, 4H), 3.95 (t, 
J = 6.0 Hz, 4H). 13C NMR (100 MHz, D2O) δ: 211.2, 59.1, 56.8. 
 
5.4.6 Synthesis of bipodal dithiocarbamate scaffold (3) 
 
 
1,3-phenylenebis(methylene)bis((pyridin-2-ylmethyl)carbamodithioate) (3) were 
synthesized from 4-aminobenzoic acid and 1,3-bis(bromomethyl)benzene within two 
steps combined. First start with the synthesis of dithiocarbamate: pyridin-2-
ylmethanamine (0.39 g, 3.6 mmol) and K2CO3 (1.38 g, 10 mmol) was slowly added in 
1,4-dioxane/water (1:4) (15 ml) was stirred for 5 min at 0 °C.  Carbon disulfide (2.72 g, 
2.20 ml, 36 mmol) was added, and it was stirred for another 60 min. The reaction was 
monitored by TLC using 19:1 DCM/MeOH. When the spot of pyridin-2-ylmethanamine 
disappears completely disappeared on the TLC plate, the second step was followed 
directly: 1,3-bis(bromomethyl)benzene (0.37 g, 1.4 mmol) was dissolved in 1,4-dioxane 
(10 ml). To this was added dropwise to the reaction mixture over a period of 10 min. 
Warmed up the solution to room temperature and stirred for 1.5 h. The reaction was 
monitored by TLC using 19:1 DCM/MeOH.  (Rf value of 1,3-bis(bromomethyl)benzene: 
0.8; Rf value of bipodal thiocarbamate scaffold: 0.4) 
 
The solution was concentrated under reduced pressure. The solid residue was 
extracted in methylene chloride (20 ml), and then washed with water. The color of 
flushing water layer turned black and the organic layer was dried over anhydrous 
Na2SO4 and volatiles were removed under reduced pressure. After washing, the crude 
product was purified by column chromatography over silica gel with methylene 
chloride/acetonitrile (9:1, v/v). 0.70 g (Yield: 75%) of 3 was obtained as a white foamy 
substance. The NMR was consistent with the assigned structure of 3. 1H NMR (400 
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MHz, CDCl3) δ 8.71 (s, 2H), 8.54 (d, J = 4.9 Hz, 2H), 7.69 (td, J = 7.7, 1.7 Hz, 2H), 7.32 
– 7.22 (m, 8H), 4.97 (d, J = 4.2 Hz, 4H), 4.54 (s, 4H). 13C NMR (101 MHz, CDCl3) δ 
196.9, 154.2, 148.9, 137.1, 137.1, 129.8, 129.0, 128.3, 122.9, 122.3, 51.3, 39.9. 
 
 
5.5 Radio-labeling experiment  
5.5.1 Radiosynthesis of [197(m)Hg]phenyl-HgCl derivatives (Method A) 
Radiosynthesis of [197(m)Hg]13: An aqueous solution of [197(m)Hg]HgCl2 (20 MBq, ca.10 
μl) was added to 1 μl (1 mg/ml stock solution) imidazole derivatives (12) in 1.5 mL 
Eppendorf vial. 20~30 μl 0.1 M HCl was added to make the final volume up to 50 µl. pH 
value of the resulting solutions was determined using Tritest-pH indicator paper (Merck) 
and remained at 1.0. Incubate the mixture at 25 °C for over 3 h (alternative 50 °C 1 h). 
Radiochemical purity of [197(m)Hg]13 was determined by radio-TLC (SG with mobile 
phase Method 1 and RP-18 with mobile phase Method 2). 
 
Radiosynthesis of [197(m)Hg]10: Considering unmodified [197(m)Hg]10 show high 
radiochemical purity when radiolabeled in 50% DMSO resulting solution. Radiolabeling 
experiments should be described respectively in this study. In 1.5 ml Eppendorf vial, 10 
μl (1 mg/ml DMSO stock solution) of tributyl(phenyl)stannane was added into aqueous 
solution of [197(m)Hg]HgCl2 (10 MBq, ca. 5 μl). 20~30 μl 0.1 M HCl together with aliquots 
volume of DMSO was added to make the final volume up to 100 µl. pH value of the 
resulting solutions was determined using Tritest-pH indicator paper (Merck) and 
remained at 1.0. Incubate the mixture at 50 °C for over 1 h ([197(m)Hg]10 with poor RCP 
at RT). Cool down the resulting mixture in ice bath before quality control. The 
radiolabeling was monitored using radio-TLC (SG with mobile phase Method 1 and RP-
18 with mobile phase Method 2). 
5.5.2 Radiosynthesis of [197(m)Hg]diphenyl-Hg derivatives (Method B) 
Radiosynthesis of [197(m)Hg]14: In 1.5 ml Eppendorf vial, an aqueous solution of 
[197(m)Hg]HgCl2 (40 MBq, ca. 20 μl) was added to 1 μl (1 mg/ml stock solution) imidazole 
derivatives (12) solution with ca. 200 μl 0.2 M MES (2-(N-morpholino)ethanesulfonic 
acid) buffer (pH 6.0~6.2). The pH value of the resulting solutions was always 
determined using Tritest-pH indicator paper (Merck). If pH value below six (mostly), ca. 
10~20 μl 1 M NaOH or 50~100 μl 0.2 M NaOH was added to keep it remained at 6.0. 
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Then, the reaction mixture was incubated in 25 °C for 60 min (alternative 50 °C 10 
min~30 min) with the final volume up to 400 µl. Before quality control, the mixture 
should be cooled down in ice bath. The extent (RCY) of 197(m)Hg-complex was 
determined by radio-TLC (SG with mobile phase Method 1 and RP-18 with mobile 
phase Method 2). 
  
Radiosynthesis of [197(m)Hg]11: Similar as [197(m)Hg]10, [197(m)Hg]11 shows weaker 
solubility in aqueous solution, which was performed in 50% DMSO either. 10 μl (1 
mg/ml DMSO stock solution) of Tributyl(phenyl)stannane was added into aqueous 
solution of [197(m)Hg]HgCl2 (10 MBq, ca. 5 μl) in a 2 ml glass bottle. To this solution, ca. 
100 μl 0.2 M MES buffer (pH 6.0~6.2) together with aliquots amount of DMSO was 
added. The final pH of the solution was kept at 6.0 and the final volume made to 500 μl. 
Thereby, ca. 10~20 μl 1 M NaOH or 50~100 μl 0.2 M NaOH was added and was 
always determined using Tritest-pH indicator paper (Merck). Then, the reaction mixture 
was incubated in 50 °C for 60 min. Before quality control, the mixture should be cooled 
down in ice bath. The radiolabeling was monitored using radio-TLC (SG with mobile 
phase Method 1 and RP-18 with mobile phase Method 2). 
 
5.5.3 Radiosynthesis of asymmetric dithiocarbamate arylmercury with 
[197(m)Hg]27 as example (Method C) 
 
 
The 1st step was the synthesis of [197(m)Hg]phenyl-Hg-Cl derivatives ([197(m)Hg]13), 
which was similar with Method A with the time extension. Briefly, 1 μl (1 mg/ml stock 
solution) imidazole derivatives (12) was added into [197(m)Hg]HgCl2 (45.5 MBq, ca. 40 
μl) solution. The reaction mixture was shaken at 25 °C overnight (~12 h). Keep the 
reaction mixture always in acid environment with a longer time interval in order to 
decompose the excess of organotin precursors slowly and avoid the production of 
diphenyl mercury derivatives. The extent (RCY) of 197(m)Hg-complex was determined by 
radio-TLC (SG with mobile phase Method 1 and RP-18 with mobile phase Method 2). 
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The 2nd step was the synthesis of [197(m)Hg]phenyl-Hg-dithiocarbamate derivatives 
([197(m)Hg]27). The 1st step resulting mixture was adjusted to pH 6 with ca. 250 μl 0.2 M 
MES (2-(N-morpholino)ethanesulfonic acid) buffer (pH 6.0~6.2) and ca. 10~50 μl 0.2 M 
NaOH before next ligands added. Then 20 μl (1 mg/ml stock solution) dithiocarbamate 
(25) containing 50 μl 0.2M MES buffer (pH 6.0~6.2) were added into the mixture slowly. 
The pH value of the resulting solutions was always determined using Tritest-pH 
indicator paper (Merck) and remained at 6.0, since neutral environment was needed to 
keep the dithiocarbamate ligands away from decomposition. Otherwise, the 
decomposed CS2 from dithiocarbamate would react with 197(m)Hg-complex and 
predicated as 197(m)HgS. The final volume was made up to 400 µl (ca.10~20% ethanol) 
with 30~40 µl ethanol. Then, incubate reaction mixture in 50 °C for 60 min. The 
radiolabeling was monitored using radio-TLC after cooled down in ice bath (SG with 
mobile phase Method 1 and RP-18 with mobile phase Method 2). 
 
 
5.6 Stability studies  
Mercury could react with two or four thiol molecules via sulfhydryl group. While an 
abundance of thiols was the main impact factor in human bodies which could 
coordinate or react with mercury. Besides, stability is needed to determine whether the 
197(m)Hg chelating units remain low potential energy (stable) under the expected 
conditions of application (in solutions for injection). Hence, several independent 
experiments are needed to determine the stability of 197(m)Hg-complexes. 
 
5.6.1 Stability studies of 197(m)Hg labeled compounds in reaction solutions 
This study was conducted to test the stability of radiolabeled mercury in reaction 
solutions. The reaction mixtures were incubated at 37 °C the in presence of same 
solution conditions for animal experiment for a period of time.  At 1 h, 24 h and 48 h, 
some of the solution was withdrawn and analyzed by radio-TLC to determine the 
variations of RCP of 197(m)Hg labeled compounds. 
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5.6.2 Stability studies (challenge studies) with thiols soaked TLC 
Normally, the sulfhydryl containing competing ligands was employed to determine the 
relative stability. The stability study (challenge study) of 197(m)Hg-chelate complexes 
were carried out on labeling complex in the excess of thiol solution directly. Then, the 
197(m)Hg reaction mixture were taken and analyzed by radio-TLC. However, radio-TLC is 
sometimes not sensitive enough to examine the trans-chelation between 197(m)Hg-
complex and thiols by the variations of Rf values. Besides, the characteristics of 
197(m)Hg-chelates was sometimes uncertain. While, [197(m)Hg]Hg-thiols would 
occasionally precipitate and contaminate the HPLC column when examined with radio-
HPLC. Consequently, thiol soaked TLC plates were developed as rapid methods to 
investigate stability of labeling products.  
 
Three different thiols (Cysteine, DMSA or NS3) were selected as the competing agents, 
in which the sulfhydryl group concentration of DMSA and NS3 are 2 and 3 times as 
Cysteine. Large excess of thiol was prepared as aliquot 10 mM stock solutions 
(Cysteine, DMSA or NS3). TLC plates (same as for RCP determination) were coated 
with these thiol solutions individually for over 12 h in room temperature. The wet plates 
were taken out and dried naturally. The eluting system were same as described in 
experimental section, including Silica Gel (Method 1) and RP-18 (Method 2). Unlabeled 
[197(m)Hg]HgCl2 in the resulting solution was determined with thiol soaked TLC plates 
first. The result showed that most of activity remained at starting point for all of the thiol 
soaked TLC plates. Because excess of thiols didn’t move with the eluting solvent, 
insoluble thiol together with 197(m)Hg-S based complex was nearly all remained at 
starting point. 
 
The availability of this challenge study was conducted on [197(m)Hg]27 as sample. 
Cysteine, DMSA and NS3 soaked TLC with clearly increasing of sulfhydryl 
concentrations were used as the competing agents to compare the affection of labeling 
efficiency. The eluting system were same as described in experimental section. As 
seen in Figure 5.1, A1: [197(m)Hg]27 moved with solvent front on cysteine soaked SG; 
A2: Rf~0.65 for [197(m)Hg]27 on cysteine soaked RP-18. B1: ~60% of [197(m)Hg]27 
moved with solvent front, while ~40% remained at starting point and in the middle of 
plate on DMSA soaked SG; B2: [197(m)Hg]27 showed as split peaks on DMSA soaked 
RP-18. It indicated that [197(m)Hg]27 reacted with DMSA and new chelates was formed. 
C1: Given that complicate mixture was obtained, the analysis is just qualitative. Less 
than 30% [197(m)Hg]27 moved with solvent front, while >60% of activity spread on the 
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NS3 soaked SG plate; C2: Rf~0.65 for [197(m)Hg]27 which estimated less than 30%, 
while >60% of activity remained at starting point on the NS3 soaked RP-18 plate. 
 
 
Figure 5.1: The stability study of [197(m)Hg]27 with competing agents A: Cysteine < B: DMSA < C: NS3 with 
the increasing of -HS concentration ratio. 
 
The study indicated that [197(m)Hg]27 as the asymmetric arylmercury showed high 
stability against the competing cysteine. However, trans-chelation was found with 
stronger thiols DMSA and more critical in the strongest competing agent NS3. The 
result proved the availability of this method. 
 
5.6.3 Stability studies (challenge studies) against thiols determined by Radio-
HPLC 
For certain compound [197(m)Hg]27, 50 μl labeling products was added into 50 μl (10 
mM) cysteine solution and the mixture was kept at 37°C. 30 μl samples were taken 
from the mixture after incubation for 1 h, 24 h and 48 h. Radio-HPLC was used to test 
the Radiochemical purity changes. Same reaction conditions were performed in DMSA 
(10 mM) challenge study. All HPLC runs are performed under the same conditions with 
the same HPLC-equipment. Column: Zorbax C18 column with inner diameter of 8 mm. 
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Mobile phase: H2O + 0.1% TFA (A) and CH3CN + 0.1% TFA (B). Flow rate: 3 ml/min. 
HPLC gradient of B phase: in 0~20 min from 45% to 80%, in 20~25 min from 80% to 
100%. 
 
 
5.7 In vivo SPECT imaging studies  
The animal experiments were performed in accordance to the guidelines of the 
German Regulations Animal Welfare. The protocol was approved by the local Ethical 
Committee for Aninal Experiments (reference number 24-9168.21-4/2004-1). Wistar 
rats (Wistar Unilever, HsdCpb: Wu, Harlan Winkelmann GmbH, Borchen, Germany) 
were housed under standard conditions with free access to standard food and tap 
water. Male Wistar rats (body weight: 180  20 g) were anesthetized with desflurane (9-
10%, 30% oxygen/air). The threshold value for breathing frequency was 65 
breaths/min. Animals were put in supine position and placed on a heating pad to 
maintain body temperature. The syringe was placed into a tail vein and was used for 
[197(m)Hg]28, [197(m)Hg]29, [197(m)Hg]2 and [197(m)Hg]HgCl2 injection (~20 MBq of in ~0.5 
ml of infusions solution with <10% ethanol). SPECT examinations were performed on a 
NanoScan® SPECT (Mediso Medical Imaging Systems, Budapest, Hungary) scanner. 
The data was evaluated with the analysis software Rover from ABX GmbH (Radeberg, 
Germany). 
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7 Appendixes 
7.1 List of abbreviations 
ACN Acetonitrile 
AFS Stomic fluorescence spectrometry 
Am Molar activity 
As Specific activity 
BFCA Bifunctional chelating agent 
BSA Bovine serum albumin 
CF2 N,N'-(azanediylbis(propane-3,1-diyl))bis(5-(morpholine-4-carbonyl)-2-
thioxo-1,3-dithiole-4-carboxamide) 
CV-AAS Cold vapor atomic absorption spectrometry 
DEOA Diethanolamine 
DiAmSar 1,8-Diamino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosine 
DMF Dimethylformamide 
DMSA meso-2,3-Dimercaptosuccinic acid 
DTC Dithiocarbamate 
DTPA Diethylenetriaminepentaacetic acid 
DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
EDTA Ethylenediaminetetraacetic acid 
EtOH Ethanol 
ESI-MS Electrospray ionisation mass spectrometry 
FBS Fetal Bovine Serum 
GIST Gastrointestinal stromal tumor 
HAc acetic acid 
HPLC High performance liquid chromatography 
ICP-MS Inductively coupled plasma mass spectrometry 
ICP-OES Inductively coupled plasma-optical emission spectrometry  
ITLC Instant thin-layer chromatography 
LET linear energy transfer 
LN LanthaNides 
MAL maleimide 
mb millibarn 
MES 2-(N-morpholino)ethanesulfonic acid 
MeOH Methanol 
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min Minute (s) 
NA Avogadro's constant 
n.c.a. No carrier added 
NHS N-hydroxysuccinimide ester 
NODAGA 2,2'-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-
triazonane-1,4-diyl)diacetic acid 
NOTA 1,4,7-triazacyclononane-1,4,7-triacetic acid 
NS2 Bis(2-(phenylthio)ethyl)amine 
NS3 Tris(2-mercaptoethyl)amine 
NTe2 Bis(2-(phenyltellanyl)ethyl)amine 
PBS Phosphate buffered saline 
PEG Polyethylene glycol 
PET Positron emission tomography 
RCP Radiochemical purity 
RCY Radiochemical yield 
ROS reactive oxygen species  
Rf Retention factor 
RIT radioimmunotherapy  
RP-18 Reverse phase-18 
Sar 3,6,10,13,16,19-hexaazabicyclo [6.6.6] icosane 
SG Silica Gel 
SPECT Single-photon emission computed tomography 
TETA 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TMK Thiomicher’s ketone 
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Supplement Figure 3: 1H NMR of 23 in D2O. 
 
Supplement Figure 4: 13C NMR of 23 in D2O 
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Supplement Figure 5: 1H NMR of 24 in D2O. 
 
Supplement Figure 6: 13C NMR of 24 in D2O. 
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Supplement Figure 7: 1H NMR of 3 in CDCl3. 
 
Supplement Figure 8: 13C NMR of 3 in CDCl3. 
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